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Progestins are used by women all over the world in menopausal hormone therapy (HT) and 
contraception. Numerous clinical trials have, however, reported that some progestins are associated 
with an increased risk for developing breast cancer. Although multiple progestins with different 
chemical structures and biological activities have been synthesised, not all progestins have been 
evaluated for increased breast cancer risk. Obesity-related inflammation is also strongly associated 
with increased breast cancer risk, particularly amongst postmenopausal women. This increased 
inflammatory state is characterised by enhanced production of pro-inflammatory cytokines, such as 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNFα). Both these inflammatory mediators 
have been implicated in breast cancer development and progression. However, the exact mechanism 
whereby inflammation and progestins contribute to breast cancer risk is yet to be established. The 
aim of this study was thus to investigate the effects of different progestins, in the absence and presence 
of IL-6 or TNFα, on the proliferation, apoptosis, migration and invasion of breast cancer cells. Given 
that some progestins can interact with multiple steroid receptors, all of which are known to play 
important roles in breast cancer biology, the first part of the study investigated effects on steroid 
receptor expression in the T47D breast cancer cell line. Western blot analysis showed that all the 
progestins decreased the expression of the estrogen receptor (ER)-subtypes, progesterone receptor 
(PR)-isoforms and the androgen receptor (AR), while no effects were observed on the expression of 
the glucocorticoid receptor (GR). This study also showed that IL-6 has no effect on steroid receptor 
expression levels, while TNFα increased the expression of the GR. Results from this study also show 
that the selected progestins differentially increased cell survival of T47D and MCF-7 BUS breast 
cancer cells, while all progestins and both inflammatory mediators increased the migration of T47D 
breast cancer cells. IL-6 had no effect on cell survival of either cell line, while TNFα decreased the 
survival of the MCF-7 BUS cells. In addition, the progestins medroxyprogesterone acetate (MPA) 
and drospirenone (DRSP), as well as IL-6, appeared to increase invasion of the MDA-MB-231 breast 
cancer cell line. In contrast, TNFα appeared to decrease invasion of the MDA-MB-231 cells. This 
study is the first to show that none of the progestin-mediated effects on steroid receptor expression, 
proliferation, apoptosis and migration were modulated by either IL-6 or TNFα. On the other hand, 
TNFα appeared to decrease the progestin-induced effects on the invasion of the MDA MB-231 breast 
cancer cell line. Taken together, the results show that even though the progestins and the pro-
inflammatory cytokines may differentially affect breast cancer growth and survival, all the selected 
progestins, as well as IL-6 and TNFα, increase migration of T47D breast cancer cells. These results 
suggest that all these progestins and the inflammatory mediators may possibly increase the risk of 
developing metastatic breast cancer. Finally, the results obtained in this study indicate that the effects 
of the progestins on steroid receptor expression and hallmarks of cancer, were not exacerbated by the 
addition of the inflammatory mediators, suggesting that the combination of inflammation and 
progestins used in HT does not further increase breast cancer risk.  





Vroue regoor die wêreld gebruik progestiene in hormoonvervanginsterapie (HVT) en as 
voorbehoedmiddels. Verskeie kliniese proewe het egter al getoon dat sommige progestiene 
geassosieer word met ŉ verhoogde kans om borskanker te ontwikkel. Hoewel verskeie progestiene 
met verskillende chemiese strukture en biologiese aktiwiteite reeds gesintetiseer is, is nie alle 
progestiene vir ŉ verhoogde borskankerrisiko geëvalueer nie. Vetsugverwante inflammasie word ook 
sterk geassosieer met ŉ verhoogde kans vir borskanker, veral onder na-menopousale vroue. Hierdie 
verhoogde inflammatoriese toestand word gekenmerk deur ŉ verhoogde produksie van pro-
inflammatoriese sitokiene, soos interleukien-6 (IL-6) en tumornekrosefaktor-alfa (TNFα). Albei 
hierdie inflammatoriese mediators is al geassosieer met die ontwikkeling en progressie van 
borskanker. Die presiese meganisme waardeur inflammasie en progestiene tot verhoogde 
borskankerrisiko bydra, is egter nog nie vasgestel nie. Die doel van hierdie studie was dus om die 
uitwerking van verskillende progestiene, in die afwesigheid en teenwoordigheid van IL-6 óf TNFα, 
op die proliferasie, apoptose, migrasie en indringing van borskankerselle te ondersoek. Aangesien 
sommige progestiene met verskeie steroïedreseptore interaksie kan hê, en almal bekend is om 
belangrike rolle in borskankerbiologie te speel, ondersoek die eerste deel van die studie die 
uitwerkings op steroïedreseptor-uitdrukking in die T47D borskankersellyn. Western klad-analise het 
getoon dat al die progestiene die uitdrukking van die estrogeenreseptor (ER)-subtipes, 
progesteroonreseptor (PR)-isoforms en die androgeenreseptor (AR) verlaag het, terwyl geen effek op 
die uitdrukking van die glukokortikoïedreseptor (GR) waargeneem was nie. Hierdie studie het ook 
getoon dat IL-6 geen effek op steroïedreseptor-uitdrukkingsvlakke het nie, terwyl TNFα die 
uitdrukking van die GR verhoog. Die resultate van hierdie studie toon ook dat die geselekteerde 
progestiene die seloorlewing van die T47D en MCF-7 BUS borskankerselle differensieel verhoog, 
terwyl alle progestiene en albei inflammatoriese mediators die migrasie van die T47D borskankerselle 
verhoog het. IL-6 het geen effek op seloorlewing van enige van die sellyne getoon nie, terwyl TNFα 
die oorlewing van die MCF-7 BUS selle verlaag het. Daarbenewens het die progestiene 
medroksieprogesteroonasetaat (MPA) en drospirenoon (DRSP), sowel as IL-6, die indringing van die 
MDA-MB-231 borskankersellyn verhoog. In teenstelling hiermee het TNFα die indringing van die 
MDA-MB-231 selle verlaag. Hierdie studie is die eerste om te wys dat geen van die progestien-
gemedieerde effekte op steroïedreseptor-uitdrukking, proliferasie, apoptose en migrasie deur óf IL-6 
óf TNFα gemoduleer is nie. Aan die anderkant het TNFα die progestien-geïnduseerde effekte op die 
indringing van die MDA-MB-231 borskankersellyn verminder. Gesamentlik wys hierdie resultate dat 
hoewel die progestiene en die pro-inflammatoriese sitokiene die groei en oorlewing van borskanker 
differensieel kan beïnvloed, kon al die geselekteerde progestiene, sowel as IL-6 en TNFα, die 
migrasie van T47D borskankerselle verhoog. Hierdie resultate dui daarop dat al hierdie progestiene 
en die inflammatoriese mediators moontlik die risiko van die ontwikkeling van metastatiese 
borskanker kan verhoog. Laastens, die resultate wat in hierdie studie verkry is, dui daarop dat die 
uitwerking van die progestiene op steroïedreseptor-uitdrukking en kenmerke van kanker nie vererger 
word deur die toevoeging van die inflammatoriese mediators nie. Dit dui daarop dat die kombinasie 
van inflammasie en progestiene wat in HVT gebruik word, nie die risiko vir borskanker verder 
verhoog nie. 
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ALPHABETICAL LIST OF ABBREVIATIONS 
AR   Androgen receptor 
bp   base pair 
DEPC   diethyl pyrocarbonate 
Dex    Dexamethasone 
DHT   5α-dihydrotestosterone 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMSO   dimethyl sulphoxide 
DNA   deoxyribonucleic acid 
DRSP   drospirenone 
E2   17β-estradiol 
ERα   Estrogen receptor alpha 
ERβ   Estrogen receptor beta 
EtOH    Ethanol 
FCS    Fetal calf serum 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GES   gestodene 
GR   Glucocorticoid receptor 
HRP   Horseradish peroxidase 
HT   Hormone Therapy 
IL-6   Interleukin 6 
LNG   levonorgestrel 
MAPK   mitogen-activated protein kinase 
Mib   Mibolerone 
MPA   medroxyprogesterone acetate 
mRNA   messenger RNA 
MTT   3-(4,5-dimethylthiazolyl)-20-2,5-diphenyltetrazolium bromide 




NET-A  norethisterone acetate 
NOMAC  nomegestrol acetate 
NFκB   nuclear factor kappa B 
PBS   Phosphate-buffered saline 
PCR   polymerase chain reaction 
PenStrep  penicillin-streptomycin 
PR   Progesterone receptor 
PR-A   Progesterone receptor-A 
PR-B   Progesterone receptor-B 
P4   Progesterone 
qPCR   Quantitative real-time polymerase chain reaction 
RLU(s)  Relative light unit(s) 
RNA   Ribonucleic acid 
RO   Reverse osmosis 
R5020   Promegestone 
SDS    Sodium dodecyl sulphate 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
TBS    Tris-buffered saline 
TBST   Tris-buffered saline-Tween 
TNFα   Tumor necrosis factor alpha  
Tris-HCl  Tris(hydroxymethyl)aminomethane hydrochloride 
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Breast cancer is a major cause of death among women (Diest et al., 2004; MacCiò and Madeddu, 
2011; Hsieh and Huang, 2016). It is a heterogenous disease classified according to receptor content 
(Hsiao et al., 2010; Turashvili and Brogi, 2017). For example, luminal breast cancer is estrogen 
receptor-alpha positive (ERα+) and progesterone receptor-positive (PR+) (ERα+/PR+) (Dai et al., 
2015; Africander and Storbeck, 2018). In contrast, basal breast cancer lacks ERα and PR expression, 
but overexpresses human epidermal growth factor receptor 2 (HER-2) (ERα-/PR-/HER-2+). Triple 
negative breast cancer (TNBC) on the other hand, lacks the expression of ERα, PR and HER-2 (ERα-
/PR-/HER-2-) (Cheang et al., 2009; Dai et al., 2015; Africander and Storbeck, 2018). More than 70% 
of breast cancers are ERα+ (Dai et al., 2016; Zahid et al., 2018), and the proliferative effects of 
estrogen via ERα are considered the main causative factors in breast cancer (Ali and Coombes, 2000; 
Chang et al., 2006; Williams et al., 2008; Cleary and Grossmann, 2009). It is thus not surprising that 
current breast cancer therapies include both inhibitors of estrogen production and ER activity (Lanari 
et al., 2012; Lim et al., 2016; Doan et al., 2017). However, some patients with ER+ breast tumours 
become resistant to these therapies (reviewed in Fan et al., 2015), while patients with ERα- tumours 
are unlikely to respond to these endocrine therapies (Collaborative Group EBCTC, 1998). In the quest 
of finding improved breast cancer therapies, other steroid receptors are now also considered as 
possible therapeutic targets. This is because steroid receptors such as the PR, androgen receptor (AR) 
and the glucocorticoid receptor (GR) are also present in breast tumours (Conzen, 2008), and emerging 
evidence indicates that these receptors not only play important roles in breast cancer biology but may 
in fact influence each other’s activity (Rizza et al., 2014; Karamouzis et al., 2015; Thomas and 
Gustafsson, 2015).  
Numerous factors have been associated with increased breast cancer risk, and include the use of 
menopausal hormone therapy (HT), contraception and being overweight or obese (Rossouw et al., 
2002; Million Women Study Collaborators, 2003; Fournier et al., 2005; MacCiò et al., 2009; Iyengar 
et al., 2013). The latter is concerning in South Africa as both breast cancer incidence and the incidence 
of obesity in women continue to increase (Hruby and Hu, 2015; South Africa Demographic and 
Health Survey (SADHS), 2016; Lince-Deroche et al., 2017; Van Zyl et al., 2017). One of the 
mechanisms suggested for the association of obesity with increased breast cancer risk is increased 
inflammation. However, the mechanism through which inflammation promotes the development of 
breast cancer is largely unknown (Iyengar et al., 2013). It has however been shown that pro-
inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα) play 
important roles in breast cancer progression (Cole, 2009; MacCiò and Madeddu, 2011).  




The incidence of obesity-related breast cancer is higher in postmenopausal women than 
premenopausal women (Marsden, 2003; Surakasula et al., 2014). Postmenopausal women often use 
HT to alleviate the symptoms of menopause, and is administered as either estrogen-only to women 
who have had a hysterectomy, or a combination of estrogen and a progestin to women with an intact 
uterus (Greendale et al., 1999; Ross et al., 2000; Rossouw et al., 2002). Although both estrogen-only 
and estrogen-progestin combination HT have been associated with increased breast cancer risk, the 
estrogen-progestin combination is associated with a greater risk (Rossouw et al., 2002; Million 
Women Study Collaborators, 2003; Fournier et al., 2005, 2008). Progestins are synthetic compounds, 
designed to have progestational activity with a greater bioavailability and half-life than the natural 
female hormone, progesterone (P4) (Speroff and Darney, 1996; Hapgood et al., 2004). Even though 
progestins were synthesised to act via the PR, numerous studies have shown that some progestins 
exert effects via other steroid receptors such as the ER, AR and GR (Guerra et al., 2013; Stanczyk et 
al., 2013; Africander et al., 2014). Multiple progestins with different structures have been synthesised 
(Schindler et al., 2003; Sitruk-Ware, 2004; Schindler, 2014), and as structure determines function, 
these progestins may have different biological activities. Not all progestins have been evaluated for 
an association with breast cancer risk, thus the possibility exists that some may not increase breast 
cancer risk. 
The ability of some progestins to activate multiple steroid receptors, together with the fact that all 
steroid receptors are expressed in most breast cancers, highlights the complexities of the mechanisms 
through which progestins may increase breast cancer risk. Comparative studies of progestin effects 
on breast cancer at the cellular level may provide insight into the mechanisms whereby these 
hormones influence breast cancer. In addition, increased production of pro-inflammatory mediators 
such as IL-6 and TNFα, as observed in obesity-related inflammation, is also associated with increased 
breast cancer risk. The exact mechanisms by which these cytokines contribute to breast cancer 
development and progression are still poorly understood. Considering that breast cancer is a major 
cause of death among women, and that the incidence of obesity is increasing, together with the fact 
that some progestins used in HT are associated with increased breast cancer risk, it is crucial to 
investigate the link between these factors and increased breast cancer risk. The following sections 
will provide an overview on the roles of endogenous hormones, progestins, steroid receptors and pro-
inflammatory cytokines in breast cancer biology. 
 
 




1.2. The importance of steroid receptors in breast cancer biology  
1.2.1. Mediators of hormone activity 
Steroid hormones elicit their biological effects by binding to intracellular steroid receptors (Xu and 
O’Malley, 2002). These receptors are a subfamily of the nuclear receptor family of transcription 
factors (DeMayo et al., 2002), and include the PR-isoforms, ER-subtypes, AR, GR and the 
mineralocorticoid receptor (MR). The well-defined domain organisations of the steroid receptors are 
depicted in Figure 1.1. These domains include a highly variable N-terminal domain which differs in 
both amino acid sequence and length, a highly conserved DNA-binding domain (DBD), a hinge 
region and a C-terminal ligand-binding domain (LBD) which is moderately conserved (McEwan et 
al., 2007; Africander et al., 2011; Perkins et al., 2018). The N-terminal domain contains an activation 
function 1 (AF-1) domain, while an AF-2 domain is found in the C-terminal LBD. Both domains are 
important for inducting the transcriptional activity of steroid receptors. However, the transcriptional 
activity of AF-2 is dependent on the presence of ligand, while AF-1 transcriptional activity is 
independent of ligand (Bourguet et al., 2000; Lavery and McEwan, 2005; Africander et al., 2011). 
Moreover, the AF-2 domain contains specific motifs that allows the interaction with co-factors, while 
these motifs are absent in the AF-1 domain (Bourguet et al., 2000; Lavery and McEwan, 2005).  
Generally, steroid receptors are activated upon hormone binding, after which the receptor undergoes 
a conformational change and the cytoplasmic hormone-bound receptor translocates to the nucleus 
(Zhou and Cidlowski, 2005; Griekspoor et al., 2007). The activated steroid receptor can then bind 
directly to DNA at specific sequences called hormone response elements (HREs) found in the 
promoter regions of target genes, thereby activating transcription (transactivation) (Kenna et al., 
1999; Klinge, 2001; Klinge et al., 2004; Platet et al., 2004). Alternatively, the activated steroid 
receptor can repress gene expression (transrepression) by tethering to DNA-bound transcription 
factors such as nuclear factor kappa B (NF-κB) (Rays et al., 1994; Yang, 1995; Paech et al., 1997). 
Even though all steroid receptors mediate their effects via similar mechanisms, they activate different 
target genes in different tissues. It is known that steroid receptors play diverse roles in breast cancer 
biology (Conzen, 2008). As studies investigating the role of the MR in breast cancer is limited, only 
the roles of the ERs, PRs, AR and GR will be discussed in the following sections.  





Figure 1.1 Structural overview of steroid receptors. Steroid receptors contain a variable amino-terminal domain (A/B) 
containing the AF-1 transactivation region, a highly conserved DNA-binding domain (DBD) (C), a hinge region (D) and 
a carboxy-terminal, ligand-binding domain containing the AF-2 transactivation region (E). A unique carboxy-terminal F 
domain can be found in ERα. The numbers indicate the length of the steroid receptors in amino acids. Redrawn from 
(Griekspoor et al., 2007; Africander et al., 2011) 
1.2.2. Estrogens and the ER subtypes 
The link between estrogen-mediated signalling and breast cancer was recognised as early as the 19th 
century (Beatson, 1896; Kelsey and Bernstein, 1996; Kuiper et al., 1996; Gustafsson, 1999). 
However, the exact role of estrogen in breast cancer is complex, and still actively researched. 17β-
Estradiol (E2) is the most biologically active estrogen (Russo et al., 1999; Russo and Russo, 2006), 
and mediates its physiological effects by binding to the ER (Horwitz & Mcguire 1978; DeMayo et 
al. 2002; Visser et al. 2013). Two functional ERs, ERα and ER-beta (ERβ), have been identified. 
These subtypes are transcribed from different genes (DeMayo et al., 2002; Conzen, 2008), and play 
opposing roles in breast cancer. For example, ERα promotes the proliferation of breast cancer cells, 
while ERβ antagonises ERα-mediated proliferation (Kuiper et al., 1996; Barkhem et al., 1998; 
Gustafsson, 1999; Lazennec et al., 2001; Platet et al., 2004; Ström et al., 2004). However, the role of 
ERβ is dependent on whether ERα is present, as it has been shown that ERβ increases breast cancer 
proliferation in ERα- breast cancer cells (Leygue and Murphy, 2013). The precise role of ERβ in ERα- 
breast cancer (TNBC) is still poorly understood, however its potential as a therapeutic target in ERα- 




breast cancer is under investigation (Honma et al., 2008; Perkins et al., 2018). Nearly 75% of breast 
cancers express ERα, and E2 together with ERα are the main etiological factors associated with breast 
cancer (Ali and Coombes, 2000; Chang et al., 2006; Williams et al., 2008; Cleary and Grossmann, 
2009). Current breast cancer therapies thus target the synthesis of endogenous estrogens and ER 
activity (Lanari et al., 2012; Lim et al., 2016; Doan et al., 2017). Estrogen synthesis is targeted by 
inhibiting aromatase, the enzyme responsible for converting androgens to estrogens (Smith and 
Dowsett, 2003; Chlebowski et al., 2009). A number of therapies are available for the inhibition of the 
ER, and include selective ER modulators (SERMs) such as tamoxifen (Jordan, 2007), and selective 
ER down-regulators (SERDs) such as fulvestrant (Ciruelos et al., 2014; Poggio et al., 2016). SERMs 
are partial ER agonists that prevent E2-mediated effects by exerting anti-estrogenic actions depending 
on the tissue type. In contrast, SERDs are ER antagonists that downregulate ER expression 
(Griekspoor et al., 2007; Ciruelos et al., 2014).  
Numerous studies have investigated the effects of E2 on the proliferation, apoptosis, migration and 
invasion of breast cancer cells (Furuya et al. 1989; van den Brûle et al. 1992; Jiang et al. 2013; Holton 
et al. 2014; Tian et al. 2018). For example, E2 is known to enhance breast cancer cell proliferation 
via both genomic and non-genomic mechanisms. Genomic mechanisms refer to the ligand-bound ER 
modulating gene expression via the ERs (Ali and Coombes, 2000; Tchafa et al., 2013), while non-
genomic mechanisms refer to rapid responses entailing the activation of membrane-bound receptors 
or the activation of protein kinase cascades (Levin, 1999; Lim et al., 2006; Marino et al., 2006; Tchafa 
et al., 2013). In addition, E2 increased the mRNA expression of Ki-67, a proliferative marker widely 
used to evaluate breast cancer cell proliferation (Klinkhammer-schalke, 2013; Dai et al., 2016; 
Mannell, 2016), via ERα in MCF-7 breast cancer cells (Liao et al., 2014). E2 is also a known inhibitor 
of apoptosis in numerous cancer cell lines, such as ovarian, lung and breast cancer cells (Mabuchi et 
al., 2004; Lewis-Wambi and Jordan, 2009; Grott et al., 2013). In breast cancer, however, the role of 
E2 on apoptosis is controversial as it has been shown to elicit both pro- or anti-apoptotic effects 
(Lewis-Wambi and Jordan, 2009). For example, E2 induced apoptosis in long-term estrogen-deprived 
MCF-7 breast cancer cells, but also inhibited apoptosis in MCF-7 and T47D breast cancer cells (Wang 
and Phang, 1995; Gompel et al., 2000; Song et al., 2001; Fernando and Wimalasena, 2004; Helguero 
et al., 2005; Lewis-Wambi and Jordan, 2009). Furthermore, it has previously been suggested that E2 
protects against apoptosis, as it enhanced the mRNA expression of the anti-apoptotic Bcl-2 gene in 
MCF-7 cells, while having no effect on the expression of the pro-apoptotic Bax gene (Wang and 
Phang, 1995). Several studies have also reported that E2 enhances the migration and invasion of MCF-
7 and T47D breast cancer cells (Albini et al., 1986; van den Brûle et al., 1992; Zheng et al., 2011; 
Shang et al., 2015), while a recent study showed that is has the ability to repress invasion of T47D 




cells (McFall et al., 2018). From the above, it is clear that E2 has the ability to enhance breast cancer 
development and progression via multiple mechanisms. Moreover, a recent study by our group 
showed that estrone (E1) and estriol (E3), two endogenous estrogens previously considered as weak 
estrogens, displayed similar agonist efficacies for transactivation as E2 via ERα and ERβ (Perkins et 
al., 2017). However, it is not only endogenous estrogens that are associated with increased breast 
cancer, but also synthetic estrogens used in postmenopausal HT regimens (Henderson et al., 1988; 
Pike et al., 1993; Greendale et al., 1999; Chervenak, 2009; Perkins et al., 2018). Further investigation 
into receptor-mediated effects of endogenous and synthetic estrogens are needed to understand the 
mechanism whereby these hormones increase breast cancer development and progression.  
1.2.3. Progestogens and the PR isoforms 
Progestogens are a class of compounds which include endogenous progesterone (P4) and progestins, 
which are synthetic hormones designed to mimic the action of P4 (reviewed in Hapgood et al. 2013). 
Progestins are used in contraception and HT instead of P4, as it has a greater bioavailability and half-
life (Speroff and Darney, 1996; Hapgood et al., 2004). In contraception, progestins are used to prevent 
pregnancy by inhibiting ovulation (Africander et al., 2011; Guerra et al., 2013). In HT, progestins are 
combined with estrogen to prevent estrogen-induced endometrial hyperplasia in women with an intact 
uterus (Johnson, 1998; Greendale et al., 1999; Ross et al., 2000; Cuzick, 2008). To date, a large 
number of progestins have been synthesised with different chemical structures (Schindler et al., 2003; 
Sitruk-Ware, 2004; Sitruk-Ware and Nath, 2010; Schindler, 2014). Most progestins are either derived 
from parent compounds such as progesterone, resulting in 17α-hydroxy-progesterone and 19 nor-
progesterone derivatives, or from testosterone, resulting in 19-nor-testosterone derivatives (Sitruk-
Ware and Nath, 2010; Africander et al., 2011). One progestin is structurally related to the MR 
antagonist, spironolactone. All progestins are classified into four consecutive generations, with the 
fourth-generation progestins designed to have a greater affinity for the PR and display biological 
effects more similar to P4 (Sitruk-Ware and Nath, 2010). Examples of progestins from different 


























































































*HT: hormone therapy; COC: combined oral contraceptive; POP: progestin-only pill; PO: progestin-only; IUD: 
intrauterine device; steroid receptors (SRs); ±: literature contradictory. Adapted from (Africander et al., 2011; Hapgood 
et al., 2013; Louw-du Toit, Storbeck, et al., 2016) 
Results from a number of clinical studies have indicated that the estrogen-progestin combination HT 
presents a higher risk for developing breast cancer than estrogen-only HT (Rossouw et al., 2002; 
Million Women Study Collaborators, 2003; Fournier et al., 2008), suggesting that the progestin 
component is responsible for the higher risk. However, the role of P4 and the progestins in breast 
cancer is not straightforward. While most studies suggest that P4 is not associated with increased 
breast cancer risk (Cordina-Duverger et al., 2013; Stute et al., 2018), there is clinical evidence that 




progestins are linked to increased risk of breast cancer (Rossouw et al., 2002; Million Women Study 
Collaborators, 2003; Fournier et al., 2008). For example, the Women’s Health Initiative (WHI) 
performed a randomized control trial on postmenopausal women using HT, and reported that the use 
of MPA in combination with estrogen is associated with an increased risk for developing invasive 
breast cancer (Rossouw et al., 2002). Additionally, the Million Women Study reported a link between 
breast cancer and the use of MPA, NET-A and LNG in HT (Million Women Study Collaborators, 
2003). Furthermore, the E3N-EPIC cohort study investigated the effects of different HT types, and 
found that the use of the early-generation progestins MPA, NET-A, as well as the fourth-generation 
progestin, NoMAC, increased the risk for developing breast cancer (Fournier et al., 2008). This 
increased risk for developing breast cancer by women using progestins in HT usage is concerning. 
However, it should be noted that not all progestins have been tested for increased breast cancer risk, 
and thus further investigation is urgently needed. Moreover, the precise mechanism whereby some 
progestogens influence breast cancer is yet to be established. 
Results from numerous studies investigating the effects of P4 and progestins in breast cancer cell lines 
are also not straightforward. For example, it has been shown that P4, MPA, NET-A, LNG and GES 
increase the proliferation of the MCF-7 and T47D breast cancer cell lines (Van den Burg et al., 1992; 
Catherino et al., 1993; Kalkhoven et al., 1994; Schoonen et al., 1995; Franke and Vermes, 2003; Lim 
et al., 2006; Izzo et al., 2014). In contrast, other studies have reported that P4, MPA and NET-A can 
inhibit proliferation of T47D breast cancer cells (Horwitz and Freidenberg, 1985; Musgrove et al., 
1991; Botella et al., 1994; Groshong et al., 1997; Formby and Wiley, 1999; Krämer et al., 2006). 
While NoMAC has been shown to inhibit proliferation of the T47D breast cancer cell line (Botella et 
al., 1994), it has also been reported to increase proliferation of the MCF-7 breast cancer cell line 
(Ruan, Schneck, et al., 2012). Most studies investigating the effects of P4 and the progestins on breast 
cancer, evaluate effects on proliferation, while only a few studies have evaluated effects on other 
cancer cell behaviours, such as apoptosis, migration and invasion (Hanahan and Weinberg, 2011). 
Results from these limited studies are, however, also inconsistent. A study from 20 years ago reported 
that P4 can induce apoptosis in the T47D breast cancer cell line (Formby and Wiley, 1998), while two 
more recent studies in T47D cells, as well as MCF-7 and MDA-MB-231 cells, report that P4 is anti-
apoptotic (Ory et al. 2001; Moore et al. 2006). The authors of the latter studies also showed that MPA 
and a synthetic PR agonist, promegestone (R5020), exert anti-apoptotic effects in T47D breast cancer 
cells (Ory et al., 2001; Moore et al., 2006), whereas others show that MPA and NET-A exert pro-
apoptotic effects in the T47D, as well as the MCF-7 breast cancer cell lines (Kandouz et al., 1999; 
Werner et al., 2005; Sweeney et al., 2014). In addition, P4, MPA, NES and DRSP can also increase 
the migration and invasion of T47D breast cancer cells, with MPA causing the highest increase (Fu 




et al., 2008, 2010). In light of the above, it is clear that more studies are needed at the cellular level. 
This will aid in the understanding of the mechanisms by which some progestins increase breast cancer 
risk, and possibly why others are not associated with such a risk. 
Progestins were designed to mimic P4 by binding to the PR. However, some progestins can also act 
via other steroid receptors such as the GR, ER and AR (Guerra et al., 2013; Stanczyk et al., 2013; 
Africander et al., 2014). For example, both MPA and NET-A can bind to the GR, with MPA 
displaying partial GR agonist activity (Koubovec et al., 2005), and NET-A antagonist activity 
(Ronacher et al., 2009). Louw-du Toit and co-workers recently reported that none of the progestins 
described in Table 1.1 could bind to ERβ, while the testosterone-derived progestins, NET-A, LNG 
and GES, could bind to ERα and display partial agonist activity (Louw-du Toit et al., 2017). Results 
from the latter study,  and an earlier study from our group, showed that MPA, NET-A, LNG and GES 
can bind to the AR and display androgenic effects similar to the natural androgen dihydrotestosterone 
(DHT) (Africander et al., 2014; Louw-du Toit et al., 2017). Like P4, however, NES, DRSP and 
NoMAC displayed AR antagonist activity (Louw-du Toit et al., 2017). The fact that progestins can 
interact with steroid receptors other than the PR, may explain some of the adverse effects associated 
with their clinical use (Koubovec et al., 2005; Africander et al., 2013, 2014; Louw-du Toit et al., 
2014). However, it is important to note that the PR itself has also been implicated with increased risk 
of breast cancer. 
The PR is found in 75% of breast cancers and exists as two isoforms, PR-A and PR-B (Horwitz & 
Mcguire 1978; Conzen 2008; Lanari et al. 2009). Although PR-A and PR-B play distinct roles in 
breast cancer, few studies distinguish between their roles. PR-A and PR-B are transcribed from the 
same gene, with PR-B having an additional amino-terminal segment of 164-amino acids (Figure 1.1) 
(Sartorius et al., 1994; Mcfall et al., 2015). While normal breast tissue expresses comparable levels 
of PR-A and PR-B (Mote et al., 2002), it is known that an imbalance of the isoforms are found in 
breast cancer, as PR-A is overexpressed (Hopp et al., 2004; Diep et al., 2015; McFall et al., 2018). 
PR-A is known to inhibit the transcriptional activity of PR-B as well as the ER (Kraus et al., 1995; 
Hopp et al., 2004). Hopp and co-workers showed that patients with breast tumours that have higher 
PR-A expression relative to PR-B expression, have an increased risk of relapse, suggesting that these 
patients are possibly resistant to tamoxifen endocrine therapy (Hopp et al., 2004). However, Lanari 
and co-workers recently suggested anti-progestins as treatment for patients with breast tumours 
expressing increased levels of PR-A, as they showed that primary tumours with increased PR-A levels 
relative to PR-B levels, regress following treatment with the anti-progestin, mifepristone (RU486) 
(Rojas et al., 2017).  




In vitro studies in breast cancer lines have shown that P4 decreased the proliferation of MDA-MB-
231 cells co-transfected with both PR-isoforms, however these authors did not investigate the role of 
the individual isoforms (Lin et al., 1999). In contrast, a study by Wargon et al. showed that the MPA-
induced increase in proliferation of T47D breast cancer cells was mediated by PR-B. First, they 
showed a role for the PR, as the response was inhibited by RU486, a PR antagonist (Wargon et al., 
2015), and next they showed that the response was abolished when the expression of PR-B was 
silenced (Wargon et al., 2015). Interestingly, Giulianelli et al. showed that ERα is required for the 
PR-B-mediated effects of MPA on gene expression and proliferation in T47D breast cancer cells 
(Giulianelli et al., 2012). Moreover, Daniel and co-workers showed that estrogen responsiveness of 
MCF-7 breast cancer cells is enhanced by PR-B (Daniel et al., 2015). In contrast, it has been shown 
that overexpression of PR-A or PR-B in MCF-7 cells decreased E2-stimulated growth, suggesting that 
the both PR isoforms can suppress growth in breast cancer cell lines expressing ERα (Zheng et al., 
2005). In agreement with the PR being associated with positive effects in breast cancer, it was recently 
shown that progestin-bound PR forms a complex with ERα, resulting in ERα binding to different 
chromatin loci and transcriptional sites (Mohammed et al., 2015), resulting in the expression of genes 
associated with a favourable outcome (Mohammed et al., 2015). However, Mohammed and co-
workers only evaluated the effects of P4 and R5020. Given that progestins have diverse structures and 
that some progestins have been associated with increased breast cancer risk, it is important to evaluate 
whether other progestins would initiate similar effects. Taken together, it is evident that the role of 
the PR in breast cancer is complex, and that it is not only dependent on the presence of ERα, but also 
on whether the PR is activated by a ligand or not. Understanding the mechanisms of different 
progestins via PR-A and PR-B is crucial, as it will provide a better understanding of the effects of 
progestins in breast cancer, while simultaneously aiding in the identification of progestins that can be 
used in HT without breast cancer risk. 
1.2.4. Androgens and the AR 
Evidence in the literature suggests that androgens and the AR play important roles in breast cancer 
biology (Conzen, 2008; Dimitrakakis and Bondy, 2009; Rizza et al., 2014). Their precise function is 
however controversial. For example, it has been suggested that androgens drive breast cancer 
development and progression by their conversion to active estrogens (reviewed in Majumder et al. 
2017). In agreement with androgens having negative effect on breast cancer, two studies have shown 
that the natural androgen DHT, as well as the synthetic non-metabolizable androgens, mibolerone 
(Mib) and methyltrienolone (R1881), increase the proliferation of the AR+ MCF-7 and MDA-MB-
453 breast cancer cell lines (Birrell et al., 1995; Doane et al., 2006). In contrast, DHT and Mib are 
also associated with positive effects on breast cancer, as a number of studies show that both these 




androgens inhibit proliferation of MCF-7, T47D and ZR-75-1 breast cancer cells (Birrell et al., 1995; 
Andò et al., 2002; Aspinall et al., 2004; Lanzino et al., 2013; Rizza et al., 2014). Differences in the 
effects of androgens on the proliferation of breast cancer cell lines have been attributed to the specific 
androgen used, its concentration and whether the ER is expressed in the cell line (reviewed in 
Somboonporn & Davis 2004). Evidence from an observational study suggest that testosterone 
administration may decrease breast cancer risk (Glaser and Dimitrakakis, 2013), while a prospective 
case-cohort study suggested that elevated levels of testosterone may lead to an increased breast cancer 
risk (Cauley et al., 1999).  
Androgens mediate their effects via the AR, which is expressed in 55% of ER- tumours and in 90% 
of ER+ tumours (Ogawa et al. 2008; Hu et al. 2011). Most studies suggest that the AR is associated 
with a good prognosis in ER+ breast cancer. Mechanisms for these positive effects have been 
suggested by studies from Peters et al. and Rizza et al., investigating the role of ERα and ERβ, 
respectively (Peters et al., 2009; Rizza et al., 2014). Peters and co-workers showed that the AR 
decreases ERα transcriptional activity by competing for the binding to an estrogen response elements 
(ERE), thereby decreasing E2-mediated effects on breast cancer cell lines (Peters et al., 2009). Indeed, 
co-expression of the AR and ERα have been associated with beneficial clinicopathological traits, 
including decreased tumour size and grade, as well as an increased response to endocrine therapy 
(Ogawa et al. 2008; Hu et al. 2011; Lundin et al. 2011; Peters et al. 2012). Rizza et al. showed that 
the AR-mediated effects of both DHT and Mib lead to an increase in the expression of ERβ, via a 
mechanism involving recruitment of the AR to an androgen response element (ARE) in the promoter 
region of ERβ (Rizza et al., 2014). Given that ERβ is known to inhibit the activity of ERα, this 
mechanism would be associated with a favourable outcome with regards to breast cancer. In ER- 
breast tumours, however, the AR is linked to poor prognosis as these tumours proliferate in response 
to androgens (Doane et al. 2006; Hu et al. 2011). Mechanistically, this could be explained by the fact 
that the AR can mimic the role of ERα in ER- breast tumors, and thus promote breast cancer 
development and progression (Agoff et al., 2003; Hu et al., 2011; Robinson et al., 2011). Given that 
the AR is widely expressed in breast tumours and that this steroid receptor is thought to correlate with 
a favourable prognosis in ER+ breast cancer, and poor disease outcome in ER- breast cancer, it is 
currently under investigation as a potential drug target (Wu and Vadgama, 2017; Giovannelli et al., 
2018). For example, use of a non-steroidal, tissue selective AR modulator (SARM), enobosarm (GTx-
24) in ER+ breast cancer patients, is showing promising results in an ongoing phase II clinical trial 
(Overmoyer et al., 2014; Overmoyer and Cancers, 2015; Giovannelli et al., 2018). A similar phase II 
clinical trial has shown a 19% clinical improvement in TNBC expressing the AR with the use of the 
AR antagonist, bicalutamide (Gucalp et al., 2013; Wu and Vadgama, 2017). 




Like DHT, the AR agonists MPA and NET-A, also inhibit the transcriptional activity of ERα via the 
AR (Peters et al. 2009; Easter Ndlovu, Stellenbosch University, MSc Thesis, 2016). These results 
suggest that these progestins may be associated with a favourable outcome in ER+ breast tumours 
expressing the AR. This raised the question whether all androgenic progestins would elicit similar 
effects, and whether it would differ for anti-androgenic progestins. On the other hand, it has also been 
shown that MPA displays anti-androgenic activity via a mechanism independent of AR binding 
(Ochnik et al., 2014). Ochnik and co-workers showed that MPA inhibits DHT-induced stabilisation 
of the AR and the anti-proliferative effects of DHT on proliferation (Ochnik et al., 2014). It is clear 
that the exact mechanism whereby progestins influence breast cancer via the AR is still poorly 
understood and that further investigation is warranted. 
1.2.5. Glucocorticoids and the GR 
The role of glucocorticoids and the GR in breast cancer is relatively understudied when compared to 
studies for the ER, PR, and AR. However, current evidence suggests that the role of the GR is not 
straightforward, as some studies report inhibitory effects by glucocorticoids, whilst others report 
increased breast cancer development and progression (reviewed in Lin & Wang 2016; Africander & 
Storbeck 2018). The natural glucocorticoid, cortisol, has been reported to increase the proliferation 
of breast cell lines derived from metastasizing breast tumours (Simon et al. 1984), while its reported 
to decrease the proliferation of MCF-7 breast cancer cells (Ryde et al. 1992). Several studies have, 
however, reported that the synthetic glucocorticoid dexamethasone (Dex) inhibits proliferation of the 
MCF-7 and T47D breast cancer cell lines (Lippman et al. 1976; Ryde et al. 1992; Vilasco et al. 2011; 
Courtin et al. 2012). Additionally, at least one study has shown that Dex inhibits apoptosis in the 
MCF-7 and MDA-MB-231 breast cancer cell lines (Wu et al., 2004).  
Glucocorticoids elicit their biological effects by binding to the GR, which is expressed in normal 
breast tissue and breast tumours (Buxant et al., 2010). Interestingly, most breast cancer cell lines also 
express the GR (Conzen, 2008; Abduljabbar et al., 2015). As with the AR, the role of the GR in breast 
cancer appears to be dependent on ERα expression. Pan et al. reported that high expression of the GR 
in ERα+ cancers is associated with a good prognosis, whereas a similar expression of the GR in ERα- 
cancers is associated with a poor outcome (Pan et al., 2011). Considering that the GR is expressed in 
about 60% of breast tumours (Abduljabbar et al., 2015), it is important to clarify its exact role in 
breast cancer biology. Finally, as some progestins are partial GR agonists, while others are GR 
antagonists (reviewed in Africander et al. 2011), further studies are required to determine whether 
these progestins influence breast cancer development and progression via the GR.  
 




1.3. The role of Inflammation and adipokines in breast cancer 
Glucocorticoids are of the most common and effective drugs used for the relief of inflammatory and 
immune disorders (Barnes, 1998; Straub and Cutolo, 2016). These hormones are generally used for 
their anti-inflammatory properties whereby they repress genes encoding pro-inflammatory cytokines 
via the GR (reviewed in Cruz-topete & Cidlowski 2016). However, glucocorticoids can also increase 
the levels of pro-inflammatory cytokines (Dhabhar, 2002; Busillo et al., 2011; Cruz-topete and 
Cidlowski, 2016). For example, pro-inflammatory cytokine levels are increased in the central nervous 
system in response to increased glucocorticoid secretion (O’Connor et al., 2003; Deinzer et al., 2004; 
Sorrells and Sapolsky, 2007; Cruz-topete and Cidlowski, 2016). Similarly, it has been found that 
MPA, a progestin with partial glucocorticoid activity, increases the expression of the pro-
inflammatory cytokine IL-12, while decreasing the expression of the anti-inflammatory cytokine IL-
10, via a GR-dependent mechanism (Louw-du Toit et al., 2014). 
There are countless factors that can cause inflammation, and include external environmental stimuli, 
acute or persistent infections, dysregulation of the immune system and autoimmune diseases 
(Grivennikov et al., 2011). Depending on the stimuli, an inflammatory response is activated by 
specific cells from the innate and adaptive immune system. However, chronic activation results in 
disrupted interactions between the immune cells, which leads to low-grade systemic inflammation. 
The latter has been linked to the development of various cancers, such as cervical, ovarian and breast 
cancer (Balkwill and Mantovani, 2001; De Visser et al., 2006; Cole, 2009).  
One of the major causes of chronic inflammation is being overweight and obese (Cleary and 
Grossmann, 2009; Iyengar et al., 2013; Zahid et al., 2018). Obesity is generally indicated by an 
increased body mass index (BMI), which is calculated by weight (kg) divided by height in meters 
squared (m2). A BMI of 25-29.9 indicates an overweight individual, while a BMI of 30 or more is an 
indication of obesity (The American Cancer Society, 2015). Mature adipocytes are no longer solely 
considered as energy-storing cells, but are recognised as active endocrine cells producing growth 
factors, hormones, cytokines, chemokines and a heterogenous group of pro-inflammatory molecules 
termed adipokines (MacCiò and Madeddu, 2011; Ouchi et al., 2011; Wang et al., 2015). The increase 
in adipocytes associated with obesity, leads to dysregulated production of adipokines such as IL-6, 
IL-1β and TNFα (Vona-Davis and Rose, 2007; Iyengar et al., 2013; Esquivel-vela et al., 2015). These 
pro-inflammatory mediators leads to increased local inflammation within the breast, which in turn 
contributes to the development of breast cancer (Iyengar et al., 2013). It has been suggested that the 
risk for developing ER+/PR+ breast tumours is higher in postmenopausal women that are overweight 
or obese (reviewed in Cleary & Grossmann 2009; Iyengar et al. 2013). However, the precise 




mechanism by which obesity-related inflammation contributes to breast cancer risk, specifically in 
postmenopausal women, is still poorly understood. 
Several hypotheses have been proposed to describe the association of obesity-related inflammation 
in postmenopausal breast cancer. For example, increased estrogen biosynthesis by the aromatase 
enzyme within the adipose tissue of the breast and the tumour itself (Rose et al., 2004; Cleary and 
Grossmann, 2009). Another hypothesis linking obesity-related inflammation to breast cancer, is that 
the adipocytes themselves may be involved in the etiopathogenesis of breast cancer (MacCiò et al., 
2009). Both in vivo and in vitro studies have shown that tumour growth is directly influenced by 
adipocytes (Iyengar et al., 2003). Numerous studies have reported that pro-inflammatory cytokines 
(adipokines) such as IL-6 and TNFα have the ability to facilitate growth and metastasis of breast 
cancer cells (Rubio et al., 2006; Sasser et al., 2007; Proietti et al., 2008; Studebaker et al., 2008), 
suggesting that these two inflammatory mediators play a central role in breast cancer pathogenesis. 
The exact role that IL-6 and TNFα play in breast cancer development and progression, however, is 
still unclear (MacCiò and Madeddu, 2011). Both these cytokines have been widely investigated and 
are also one of the focus points of this study. In the following sections, a brief overview is provided 
on the role of IL-6 and TNFα in breast cancer biology. 
1.3.1 TNFα and breast cancer 
TNFα is a crucial protein involved in the inflammatory response, and is implicated in numerous 
diseases (Cabal-hierro and Lazo, 2012). Although this pro-inflammatory cytokine is primarily 
synthesised by immune cells such as mast cells, dendritic cell lymphocytes and macrophages, it is 
also  produced by adipocytes (MacCiò and Madeddu, 2011). In fact, TNFα was the first pro-
inflammatory adipokine to be recognised as a product of adipocytes (MacCiò and Madeddu, 2011). 
However, the extent to which TNFα is secreted into circulation is unknown (MacCiò and Madeddu, 
2011).  
TNFα mediates its responses through two distinct glycoprotein transmembrane receptors known as 
TNF receptor-1 (TNFR1) and TNFR2 (Cabal-hierro and Lazo, 2012; Waters et al., 2013; Martínez-
reza et al., 2017). The expression of these receptors have been shown in breast cancer tissue (Waters 
et al., 2013; Yang et al., 2017), as well as in breast cancer cell lines such as the T47D, MCF-7 and 
MDA-MB-231 cells (Zhao et al., 2017). Most biological effects of TNFα occur via activation of 
TNFR1 (Wajant et al., 2003; Martínez-reza et al., 2017). Generally, TNFα activates three diverse 
cellular responses which include cell death, cell survival and transcription of other pro-inflammatory 
genes (reviewed in Waters et al. 2013). Evidence on the effects of TNFα on breast cancer cells are 
not always straightforward. In fact, Wang et al. refers to TNFα as a “double-dealer” with regards to 




cancer (Wang and Lin, 2008). This is due to the fact that TNFα can a drive cancer cell proliferation, 
metastasis and tumour angiogenesis, while it can also induce cell death (Wang and Lin, 2008). Results 
from in vitro studies in cells lines have shown that TNFα promotes proliferation in T47D breast cancer 
cells (Rubio et al., 2006), while inducing apoptosis in the MCF-7 breast cancer cell line (Katerinaki 
et al., 2003; Wajant et al., 2003; Wang and Lin, 2008). In contrast to the latter, at least two studies 
have shown that TNFα has no effect on apoptosis in T47D cells (Rubio et al., 2006; Wang and Lin, 
2008). Together these results suggest that TNFα exerts cell line-specific effects. In addition, Wolczyk 
et al. showed that TNFα promotes the growth, migration and invasion of both the ERα+ MCF-7, and 
ERα- MDA-MB-231, breast cancer cell lines, via a mechanism involving the activation of the 
mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway as 
well as increased expression of matrix metalloproteinases (MMPs) (Wolczyk et al., 2016). MMPs are 
zinc-containing endopeptidases (Hu and Beeton, 2010) that play an important role in the early stages 
of cancer invasion, as they cleave the main constituents of the cell basement membrane, namely type 
IV collagen, elastin and laminin (Toth and Fridman, 2001; Gach et al., 2011; Wolczyk et al., 2016). 
MMP-2 and MMP-9, also referred to as gelatinase A and gelatinase B, respectively, can hydrolyse 
denatured gelatin (collagen I) (Murphy and Crabbe, 1995) and their expression and activities are often 
investigated as a measure of invasion (Toth and Fridman, 2001; Hu and Beeton, 2010). For example, 
Wolczyk and co-workers showed that TNFα dose-dependently increased the expression of MMP-9, 
while having no significant effect on MMP-2 expression in MCF-7 and MDA-MB-231 breast cancer 
cell lines (Wolczyk et al., 2016). As MMP-9 is essential for sustained invasion in tumour cells, these 
results suggested that TNFα may play a role in enhancing migration and invasion of breast cancer 
cells (Raghu et al., 2010; Wolczyk et al., 2016). It is evident that the function of TNFα in breast 
cancer is not yet well understood (Martínez-reza et al., 2017), and that further studies are required to 
gain clarity on its role in breast cancer pathogenesis. Given the fact that steroid receptors play crucial 
roles in breast cancer, one possible mechanism that has not been investigated, is whether TNFα may 
influence steroid receptor expression levels. 
1.3.2 IL-6 and breast cancer 
TNFα upregulates the expression of IL-6 (Suarez-Cuervo et al., 2003), and increased production of 
IL-6 has been observed in a variety of chronic inflammatory disorders (Feghali et al., 1997). IL-6 
serum levels are also increased in breast cancer patients (Zhang and Adachi, 1999; Vozarova et al., 
2001; Slattery et al., 2008) as well as in menopausal women (Morley and Baumgartner, 2004). As 
IL-6 can be produced by immune cells, tumour cells, adipose cells or a combination of the three 
(Knüpfer & PreiB 2007; Gyamfi et al. 2018), the exact source of the increased IL-6 serum levels in 
breast cancer patients and menopausal women are unknown. It is, however, known that about a third 




of the elevated circulating levels of IL-6 originate from adipose tissue (Fernandez-Real and Ricart, 
2003).  
IL-6 mediates its effects by binding to the IL-6 receptor (IL-6R), which forms part of the cytokine 
receptor class I superfamily (Kershaw and Flier, 2004). The receptor exist as two forms, a ± 50 kDa 
soluble form and a ± 80 kDa membrane-bound form (Kershaw and Flier, 2004), which are both found 
in breast cancer tissues and cell lines (Chiu et al., 1996; Knüpfer and Preiss, 2007). Although a 
number of studies have investigated the effects of IL-6 on breast cancer cell lines (Chiu et al., 1996; 
Badache and Hynes, 2001; Sasser et al., 2007; Studebaker et al., 2008; Gallo et al., 2018), the 
evidence is not always consistent. Some studies have reported that IL-6 increases proliferation of the 
MCF-7 breast cancer cell line (Sasser et al., 2007; Studebaker et al., 2008), while another showed 
that it inhibits the growth of these cells (Chiu et al., 1996). In addition, prolonged treatment with IL-
6 can induce apoptosis in the ER+ MCF-7 cells, but not in the ER- MDA-MB-231 cells (Chiu et al., 
1996). A study by Badache and Hynes reported that IL-6 inhibits the growth of T47D breast cancer 
cells, while enhancing the migration in this cell line (Badache and Hynes, 2001). Similarly, Gallo and 
colleagues reported that IL-6 plays an important role in the progression of breast cancer by promoting 
the migration of MCF-7 and MDA-MB-231 breast cancer cells (Gallo et al., 2018). Results from an 
in vivo study has also showed that increased levels of IL-6 are linked to enhanced metastasis and 
increased breast tumour size (Dirat et al., 2011). Moreover, like TNFα, IL-6 stimulates estrogen 
production by increasing aromatase expression within malignant breast tissue as well as adipose tissue 
(Purohit et al., 1995, 2002; Suarez-Cuervo et al., 2003; Irahara et al., 2006). Overall, the current 
evidence in the literature suggests that IL-6 may contribute to breast cancer risk via several 
mechanisms. As discussed for TNFα, the influence of IL-6 on the expression levels of steroid 
receptors in breast cancer cells is unknown and may be a possible mechanism whereby this cytokine 
influences breast cancer risk. 
1.4 Conclusion 
Progestins, in combination with estrogen, are widely used by postmenopausal women in HT 
(Johnson, 1998; Greendale et al., 1999; Ross et al., 2000; Cuzick, 2008; Africander et al., 2011; 
Guerra et al., 2013). These estrogen-progestin HT regimens have been associated with increased risk 
for developing breast cancer (Rossouw et al., 2002; Million Women Study Collaborators, 2003; 
Fournier et al., 2008), that are notably higher than risk with estrogen-only regimens. Although 
progestins were designed to mimic P4 by binding to the PR, some progestins bind to other steroid 
receptors, such as the GR, ER and AR (Guerra et al., 2013; Stanczyk et al., 2013; Africander et al., 
2014). Thus, it is possible that multiple steroid receptors may be implicated in the mechanism for 




increased breast cancer risk by progestins. For example, MPA has been shown to increase migration 
and invasion of breast cancer cells via the PR (Fu et al., 2008), while it has also been reported that 
ERα is required for MPA-induced breast cancer proliferation via PR-B (Giulianelli et al., 2012). 
Mechanisms other than direct steroid receptor binding may also be involved, as MPA has previously 
been shown to inhibit DHT-induced stabilisation of the AR and the anti-proliferative effects of DHT 
in normal breast epithelial cells, without activating the AR itself (Ochnik et al., 2014). Multiple 
generations of progestins have been synthesised with different chemical structures (Schindler et al., 
2003; Sitruk-Ware, 2004; Sitruk-Ware and Nath, 2010; Schindler, 2014), and only a few have been 
evaluated for their risk in terms of breast cancer.   
Low-grade chronic inflammation is also strongly linked to the development and progression of breast 
cancer (Cleary and Grossmann, 2009; Cole, 2009; Pierce et al., 2009), with obesity being one of the 
major contributing factors associated with an increased inflammatory state (Ouchi et al., 2011). It is 
believed that the elevated levels of circulating pro-inflammatory cytokines, also known as adipokines 
when produced by adipocytes, contribute to the onset and development of breast cancer (Vona-Davis 
and Rose, 2007; Iyengar et al., 2013). Two specific pro-inflammatory cytokines, IL-6 and TNFα, are 
found within both adipose tissue and breast tumours, and have been reported to facilitate tumour 
growth and metastasis (Rubio et al., 2006; Sasser et al., 2007; Proietti et al., 2008; Studebaker et al., 
2008). However, the exact mechanism linking chronic inflammation and breast cancer is still poorly 
understood. Whether effects of cytokines such as IL-6 and TNFα on steroid receptor expression levels 
in breast cancer cells may also be a possible mechanism is not known. This is important as all steroid 
receptors have been implicated in breast cancer pathogenesis (Conzen, 2008).  
Although a number of studies have investigated the effects of IL-6, TNFα and some progestins at the 
cellular level, results from these studies are often contradictory. Considering that many questions on 
the effects of IL-6 and TNFα on breast cancer remain unanswered, and that a wide range of progestins 
are available for clinical use, it is clear that more molecular studies are required to compare the effects 
of these cytokines and different progestins on breast cancer risk. Postmenopausal women have a 
greater risk for developing breast cancer associated with obesity-related inflammation, than 
premenopausal women (MacCiò and Madeddu, 2011). As postmenopausal women often use HT to 
relieve menopausal symptoms, the question arises whether there is any direct association between 
inflammation, progestins used in HT and breast cancer. Studying these factors at a molecular level 
will aid in our understanding of what may be driving inflammation- and HT-associated breast cancer. 




1.5 Hypothesis and Aims 
It is evident that obesity-related inflammation and some progestins used in HT are associated with an 
increased risk of breast cancer (Rossouw et al., 2002; Million Women Study Collaborators, 2003; 
Fournier et al., 2008; MacCiò and Madeddu, 2011; Iyengar et al., 2013) (Figure 1.2). However, not 
all progestins have been evaluated for this risk. Moreover, the precise mechanism for the association 
between obesity-related inflammation and breast cancer, as well as progestins and breast cancer, are 
not known.  
 
Figure 1.2 Illustration of the known and unknown links between HT, inflammation and breast 
cancer. (Figure compiled by author (A. Eksteen); images sourced through www.google.com – 
licenced for non-commercial reuse) 
The primary hypothesis of this study was that the selected progestins and natural female hormones 
would elicit differential effects on steroid receptor expression and hallmarks of breast cancer. 
Considering that pro-inflammatory mediators such as IL-6 and TNFα are also associated with 
increased breast cancer risk (Nojek et al., 2006; Sasser et al., 2007; Proietti et al., 2008; Studebaker 




et al., 2008), it was hypothesised that these differential effects of the progestins would be exacerbated 
in the presence of IL-6 and TNFα. 
Using various breast cancer cell lines as in vitro model systems for breast cancer, such as the human 
ERα+ MCF-7 BUS and T47D breast cancer cell lines, as well as the human ERα- MDA-MB-231 cells, 
the aims of the study were as follows: 
1. To directly compare the effects of selected progestins and the natural female hormones, 
as well as IL-6 and TNFα on steroid receptor expression using western blotting. 
2. To directly compare the effects of selected progestins and the natural female hormones, 
as well as IL-6 and TNFα on the following hallmarks of cancer: 
A. Proliferation, using a combination of cell viability assays and quantitative real-time 
polymerase chain reaction (qPCR) analyses. The latter is for the evaluation of the 
mRNA expression of the well-known marker of proliferation, Ki-67. 
B. Apoptosis, using the Caspase-Glo 3/7 apoptosis detection assay kit as well as qPCR 
analyses for the mRNA expression of the pro- and anti-apoptotic markers, Bax and 
Bcl-2. 
C. Migration, using the scratch wound-healing assay. 
D. Invasion, using the gelatin zymography and transwell assays. 
3. To determine whether IL-6 and TNFα modulate the effects of the progestins and the 
natural female hormones on steroid receptor expression as well as on breast cancer cell 
proliferation, apoptosis, migration and invasion. 
  












MATERIALS AND METHODS 
  




2.1. Cell lines and mammalian tissue culture 
The MCF-7 BUS human breast cancer cell line, a gift from Prof. A. Soto (Tufts University, 
Massachusetts, USA), was maintained in phenol-red Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma-Aldrich, South Africa (SA)) supplemented with 5% heat-inactivated fetal calf serum (FCS) 
(Separations, SA) and 1% penicillin-streptomycin (PenStrep) (50 IU/mL penicillin and 50 µg/mL 
streptomycin) (Sigma-Aldrich, SA). The T47D human breast cancer cell line, obtained from Prof. I. 
Parker (University of Cape Town, SA), was maintained in phenol-red DMEM supplemented with 
10% FCS and 1% PenStrep. The MDA-MB-231 human breast cancer cell line, a kind gift from Prof. 
A. Edkins (Rhodes University, SA), were maintained in the same medium as the T47D breast cancer 
cell line, plus 2 mM L-glutamine (Sigma-Aldrich, SA). The cell lines used in this study were selected 
based on their cellular properties such as steroid receptor content, their ability to respond to hormones 
as well as their metastatic potential (see Table 2.1). Cells were regularly tested for mycoplasma 
infection by means of Hoechst staining (Chen, 1977) and only mycoplasma negative cells (Addendum 
B, Figure B1) were used for experiments. All cells were maintained in 75 cm2 tissue culture flasks 
(Bio-Smart Scientific, SA) at 37°C, with 90% humidity and 5% CO2. 






ERα, ERβ, PR-A, PR-B, 
AR, GR (Horwitz et al., 
1975; Singer et al., 2003) 
Estrogen-dependent, proliferative, non-
metastatic, poorly invasive (Horwitz et al., 
1978; Lee et al., 2015) 
T47D 
ERα, ERβ, PR-A, PR-B, 
AR, GR (Horwitz et al., 
1978; Singer et al., 2003) 
Proliferative, non-metastatic, poorly 
invasive (Gordon et al., 2003; Ström et al., 
2004) 
MDA-MB-231 
ERβ, GR (Horwitz et al., 
1978; Vladusic et al., 2000) 
Estrogen-independent, proliferative, 
metastatic, highly invasive (Cailleau et al., 
1974; Kang et al., 2003) 
2.2. Test compounds 
The natural female hormones, 4-Pregnene-3,20-dione [Progesterone; P4] and 17β-estra-1,3,5(10)-
etriene-3,17 diol [17-β-estradiol; E2], as well as the progestins, 6α-methyl-17α-hydroxyprogesterone 
acetate [medroxyprogesterone acetate; MPA], 17α-ethynyl-19-nortesterone 17β-acetate [norethisterone 
acetate; NET-A], 13-ethyl-17-ethynyl-17-hydroxygon-4-en-3-one [levonorgestrel; LNG], 17-




ethinyl-17-hydroxy-18-methylestra-4,15-dien-3-one [gestodene; GES], 6, 7, 15, 16-
dimethylene-3-oxo-17-pregn-4-ene-21,17 carbolactone [drospirenone; DRSP] and 17-acetoxy-6-
methyl-19-norpregna-4,6-dione-3,20-dione [nomegestrol acetate; NOMAC], as well as the synthetic 
glucocorticoid dexamethasone (Dex) and the selective estrogen receptor modulator, tamoxifen, were 
purchased from Sigma-Aldrich, SA. The synthetic PR ligand promegestone, R5020, was purchased 
from PerkinElmer, SA, while the synthetic androgen mibolerone (Mib), was obtained from Steraloids, 
(United States of America). TNFα and IL-6 were purchased from ThermoFisher, SA. Lyophilised 
TNFα was reconstituted in sterile, distilled water to a concentration of 0.1 mg/mL, whereas IL-6 was 
reconstituted in 100 mM acetic acid to a concentration of 1 mg/mL. Further dilutions of TNFα and 
IL-6 were made using phenol red-free DMEM supplemented with 10% FCS. All test compounds 
were prepared using absolute ethanol and stored at −20˚C in light-protective vials. For all experiments 
the compounds were diluted 1000 times in phenol red-free DMEM (Sigma-Aldrich, SA) resulting in 
a final ethanol (EtOH) concentration of 0.1% (v/v). Thus, 0.1% (v/v) EtOH was used as a solvent 
control for all experiments.  
2.3. Western Blot Analysis 
T47D breast cancer cells were seeded into 12-well plates at a density of 2x105 cells per well. The 
next day, cells were treated for 24 hours with either 0.1% (v/v) EtOH or 100 nM of the hormones in 
the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα in unsupplemented phenol red-free 
DMEM. Following treatment, the medium was aspirated and the cells lysed with 80 μL 2X Laemmli 
SDS sample buffer (Addendum A). The cell lysates were then boiled at 95°C for 10 minutes and 
denatured protein lysates were stored at -20°C until analysis. Protein samples were separated by 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE) at 100 V for 15 
minutes, followed by 200 V for 1 hour in 1X SDS-PAGE running buffer (Addendum A). Following 
electrophoresis, the separated proteins were transferred to nitrocellulose membranes (AEC-
Amersham Biosciences, SA) using 1X transfer buffer (Addendum A). The membranes were 
subsequently blocked for 90 minutes in 10% (w/v) fat-free milk powder made in Tris-buffered saline 
(TBS) containing 0.01% (v/v) Tween-20 (TBST) (Addendum A). The membranes were subsequently 
washed in TBST once for 15 minutes, twice for five minutes, followed by another five-minute wash 
in TBS at room temperature with agitation. The membranes were then probed with specific primary 
antibodies (see Table 2.2) at 4°C for 16 hours. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was used as the loading control. Following the incubation with the primary antibody, membranes 
were washed as previously described and incubated with the appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibodies for 90 minutes at room temperature with agitation (Table 
2.2). The secondary antibody dilutions were prepared in 10% (w/v) fat-free milk powder made in 




TBST. The membranes were subsequently washed with TBST as described above and the proteins of 
interest visualized by means of chemiluminescence using the Clarity™ Western ECL Substrate (Bio-
Rad, SA) and the MyECL Imager (Thermo Scientific, SA). Images were analysed using the 
MyImageAnalysis™ software version 2.0 (Thermo Scientific, SA). 
Table 2.2 Specific antibodies and dilutions used for Western blot analyses. 
Protein Primary Antibody  Secondary Antibody  
ERα 1: 1000 (ERα HC-20) 1 1: 1000 (goat anti-rabbit) 
ERβ 1: 500 (EPR3777) 2 1: 1000 (goat anti-rabbit) 
PR-A/B 1: 1000 (PR-A/B H-150) 3 1: 2000 (rabbit anti-mouse) 
AR 1: 1000 (AR 441) 1 1: 3000 (rabbit anti-mouse) 
GR 1: 3000 (GR H-300) 1 1: 4000 (goat anti-rabbit) 
GAPDH 1:3000 (GAPDH 0411) 1 1: 4000 (rabbit anti-mouse) 
1 ERα, AR, GR, GAPDH, goat-anti-rabbit, rabbit anti-mouse: Santa Cruz Biotechnology, Inc, SA 
2 ERβ: Abcam, SA 
3 PR-A/B: Leica Biosystems, SA 
2.4.  Cell viability assays 
MTT (3-(4,5-dimethylthiazolyl)-20-2,5-diphenyltetrazolium bromide) cell viability assays were 
conducted to evaluate effects on proliferation of breast cancer cell lines as previously described, but 
with a few modifications (Mosmann, 1983; Verhoog et al., 2007). Briefly, the MCF-7 BUS cells were 
serum starved in phenol red-free DMEM, supplemented with 5% heat-inactivated charcoal-stripped 
FCS (Addendum A) and 1% PenStrep for one week, before seeding the cells into 96-well plates at a 
density of 5 x103 cells per well using phenol red-free DMEM supplemented with 5% heat-inactivated 
charcoal-stripped FCS and 1% PenStrep. The T47D and MDA-MB-231 cell lines were maintained 
as described in Section 2.1 before seeding at 1x104 cells per well. The next day, cells were treated for 
72 hours with 0.1% (v/v) EtOH (vehicle control) or 100 nM of the hormones in the absence and 
presence of 5 ng/ml IL-6 or 20 ng/ml TNFα in supplemented phenol red-free DMEM at 37˚C in 90% 
humidity and 5% CO2. Following the incubation, the medium was aspirated and the cells were re-
treated with new/fresh test compounds for a further 48 hours. Four hours prior to the end of the total 
120-hour period, 50 µL of the colorimetric MTT (Sigma-Aldrich, SA) solution (Addendum A) and 
150 µL phenol red-free DMEM was added to each well. The yellow MTT thiazole solution was 
reduced by metabolically active cells to form purple, insoluble formazan crystals. The solution was 
carefully aspirated and the formazan crystals solubilised in 200 µL dimethyl sulphoxide (DMSO). 




The absorbance was measured at 550 nm in the BioTek® Power Wave 340 microplate 
spectrophotometer (Analytical and Diagnostic Products, SA). Results were expressed as fold induction 
relative to 0.1% (v/v) EtOH (vehicle) set as one. 
2.5. Apoptosis Assay 
To measure apoptosis the Caspase-Glo 3/7 apoptosis detection assay kit was used (Promega, Anatech, 
SA). It measures the activities of the caspase-3 and caspase-7 enzymes, which are known to drive 
apoptosis. This specific assay relies on caspase-3 and caspase-7 cleaving the caspase-3/7 pro-
substrate containing a DEVD tetrapeptide sequence, which is the recognition site for these enzymes. 
After cleaving of the substrate, aminoluciferin is released which reacts with luciferase and produces 
measurable light. The amount of luciferase measured is proportional to the amount of caspase activity. 
The MCF-7 and T47D breast cancer cell lines were maintained as described in Section 2.1. The cells 
were seeded into High Binding Isoplate–96 HB, white framed 96-well plates (PerkinElmer, 
Massachusetts, USA) at a density of 1 x 103 cells per well and left to settle. The following day, the 
cells were treated with 0.1% (v/v) EtOH or 100 nM of the hormones in the absence and presence of 
5 ng/ml IL-6 or 20 ng/ml TNFα in unsupplemented phenol red-free DMEM for 6 or 24 hours for the 
MCF-7 BUS and T47D breast cancer cells, respectively. After the incubation period has lapsed, 100 
μL of the Caspase-Glo 3/7 substrate was added to the cells without aspirating the medium. The plates 
were then covered with plate sealers and lids, before the contents of the wells were gently mixed on 
a shaker at 30 rpm for 30 seconds. The plates were incubated at room temperature for a further 2 
hours before the luminescence of each sample was read using a luminometer (Veritas, Whitehead 
Scientific, SA). The following controls were included in each experiment: cell culture medium 
without cells (blank) and cell culture medium with vehicle (0.1% (v/v) EtOH) treated cells (vehicle 
control). The data presented is the fold caspase 3/7 activity, where the blank was subtracted from each 
sample value, and the relative light units (RLU) of each sample was set relative to the vehicle treated 
cells set as one. 
2.6. Migration (Scratch wound-healing) assay 
The T47D breast cancer cells were maintained as described in Section 2.1 and seeded into 24-well 
plates at a density of 2.5 x 105 cells per well in supplemented phenol red-free DMEM. Cells were 
grown to confluence and treated with 5 µg/mL Mitomycin C (Sigma-Aldrich, SA), an inhibitor of 
proliferation, for 2 hours (Tomasz, 1995). The medium was subsequently aspirated and a thin 
“scratch/wound” was made on the cell monolayer using a 200 µL pipette tip. Cell debris was removed 
by washing the cells with pre-warmed 1X phosphate buffered saline (PBS), prior to treatment with 




0.1% (v/v) EtOH or the test compounds for 72 hours. Using an inverted microscope (Olympus IX81 
inverted fluorescent microscope at 4X magnification), an image indicating the initial wound was 
captured directly after treatment (zero hours), followed by capturing of images every 24 hours over a 
period of 72 hours. Image J software was used to quantify the wound area and the percentage 
migration of the cells relative to the initial wound area was calculated. 
2.7. Invasion assays 
2.7.1. Gelatin zymography assay 
T47D breast cancer cells were maintained as in Section 2.1 and seeded into 6-well plates at a density 
of 2.5x105 cells per well in phenol-red free DMEM supplemented with 10% CS-FCS and 1% 
PenStrep. The following day, the cells were incubated with the test compounds in unsupplemented 
phenol red-free DMEM for 24 hours. After the incubation period, the supernatants containing secreted 
proteins, were collected in 2 mL microcentrifuge tubes and kept on ice. To remove any cell debris, 
the microcentrifuge tubes containing the supernatant were centrifuged at 400 x g for 5 minutes at 4°C. 
After centrifugation, the supernatant was removed and placed into clean microcentrifuge tubes. The 
samples were diluted with 4X sample buffer (Addendum A) and 15 μL was loaded in the same order 
onto two 10% acrylamide gels containing 1% gelatin. Gel electrophoresis was performed at 90 V for 
approximately two hours using 1x SDS-PAGE running buffer (Addendum A). One gel (the total 
protein loading control) was stained with Coomassie blue stain solution (Addendum A) for 30 
minutes on a shaker at room temperature and rinsed with a destain solution (Addendum A) until clear 
blue bands were visible. To assess gelatin degradation, 100 mL of renaturing buffer (Addendum A) 
was added to the second gel and incubated for 30 minutes at room temperature with agitation. The 
buffer was removed and the step repeated. Thereafter, the gel was incubated with 100 mL developing 
buffer (Addendum A) in a sealed container overnight at 37°C. The following day, the gel was stained 
and destained as above. Photographs of the gels were captured with the Bio-Rad Molecular Imager 
Gel Doc XR+ with Image Lab Software system. The intensity of the bands on both gels were 
quantified according to Hu & Beeton (Hu and Beeton, 2010). The value of each sample was then 
divided by the total protein of that specific sample and set relative to the vehicle control. 
2.7.2. Transwell assay 
For the cell invasion assay, 24-well polycarbonate transwell inserts containing 8.0 µm pore filter 
membranes (Corning, Inc., Corning, NY) were placed into the wells of a 24-well tissue culture plate 
(Wang and Rao, 2014). The filter membrane was coated with 100 μL of 100 μg/mL Corning matrigel 
matrix (BD Biosciences). The matrigel was allowed to dry for 6 hours at 37°C, with 90% humidity 




and 5% CO2. The MDA-MB-231 cell line was maintained as in Section 2.1 and 2x10
5 cells in 
unsupplemented phenol red-free DMEM gently added into the upper chamber (insert) of each well. 
The plates were incubated for 30 minutes at 37°C and 5% CO2 to allow the cells to settle. Thereafter, 
the cells were treated with either 0.1% (v/v) EtOH (control) or 100 nM MPA or DRSP in the absence 
and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα. Phenol red-free DMEM supplemented with 10% 
charcoal-stripped FCS (chemo-attractant) was added to the bottom chamber of each well and the 
plates incubated for 24 hours. After the 24-hour incubation, the transwell insert was removed and 
excess cells that did not migrate removed by carefully swabbing the inside of the insert with a cotton 
swab. These inserts were then washed twice with 1X PBS before fixing the cells by placing the inserts 
into 1 mL 70% (v/v) EtOH for 10 minutes. The inserts were again washed twice with 1X PBS and 
left to air dry. The cells on the transwell inserts were subsequently stained with 1 mL 0.2% crystal 
violet for 20 minutes at room temperature. Excess crystal violet was carefully removed by washing 
the transwell insert with 1X PBS and allowing it to dry. A widefield confocal microscope (Carl Zeiss 
LSM780 with ELYRA PS1 Super-resolution platform) was used to capture images of the cells on the 
membrane. For quantification of migration, the cells on the membrane were dissolved in 33% glacial 
acetic acid and the absorbance measured at 590 nm.  
2.8. Isolation of total RNA 
T47D and MCF-7 BUS breast cancer cell lines were maintained as described in Section 2.1 and 
seeded into 12-well plates at a density of 1x105 cells per well in supplemented phenol-red free DMEM 
and allowed to settle for 24 hours. The cells were then treated with either 0.1% (v/v) EtOH (vehicle) 
or 100 nM E2 or MPA in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα in 
unsupplemented phenol red-free DMEM for 24 hours. Following a single PBS wash, total RNA was 
isolated from the cells using Tri-Reagent (Sigma-Aldrich, SA) according to the manufacturer’s 
instructions. Briefly, cells were lysed by adding 400 µL Tri-Reagent. To facilitate lysis, the cells were 
placed at -80°C and then thawed. The thawed cell lysates were then transferred into 1.5 mL 
microcentrifuge tubes and incubated at room temperature for 5 minutes. Total RNA was extracted by 
adding 80 µL chloroform, vortexing for 15 seconds and incubating the samples at room temperature 
for 2-3 minutes. The samples were then centrifuged at 14000 xg for 15 minutes at 4°C. The aqueous 
phase containing the RNA was transferred into a clean microcentrifuge tube. An equal volume of ice-
cold isopropanol was added to the microcentrifuge tube containing the aqueous phase and this was 
vortexed for 15 seconds. The samples were then incubated for 15 minutes at room temperature, 
followed by centrifugation at 14000 xg for 15 minutes at 4°C to pellet the RNA. The pellets were 
washed with 500 µL 75% (v/v) EtOH (diluted using diethyl pyrocarbonate (DEPC) water) and 
vortexed for one minute before centrifugation at 8 000 xg for 5 minutes at 4°C. The supernatant was 




removed and the RNA pellets air-dried for 10 minutes on ice. RNA pellets were subsequently 
dissolved in DEPC-treated water and the concentration and purity assessed by measuring the 
A260/A280 ratio using a NanoDrop (ND-100 Spectrophotometer). The integrity of the RNA was 
confirmed by assessing the presence of intact 28S and 18S ribosomal RNA subunits on a 1% w/v 
denaturing agarose gel (Aranda et al., 2012) (Addendum B, Figure B2). RNA samples were stored at 
-80°C. 
2.9. cDNA synthesis 
Total RNA was reverse-transcribed using the ImProm-IITM Reverse Transcription System (Promega, 
USA) according to the manufacturer’s instructions. Briefly, for each RNA sample 0.5 µg RNA and 
33.3 μM oligo(dT) primer was added into a thin-walled PCR tube. Nuclease-free water was 
subsequently added to a final volume of 2.5 µL and the mixture was incubated for 5 minutes at 70°C 
to denature the RNA. Thereafter, the samples were placed on ice for 5 minutes. The following master 
mix of the rest of the components needed for the reverse transcription reaction was prepared per RNA 
sample: 3.5 μL nuclease free water, 2 μL ImProm-II 5X reaction buffer, 1 mM MgCl2, 0.5 nM dNTPs, 
10 U recombinant RNasin ribonuclease inhibitor and 80 U ImProm-II reverse transcriptase. A volume 
of 7.5 µl of the master mix was added to each sample. Samples were incubated for 5 minutes at 25˚C 
to allow annealing of the oligo(dT) primers. This was followed by incubation for 1 hour at 42˚C for 
extension. Samples were then placed at 70˚C for 15 minutes to inactivate the reverse transcriptase 
enzyme and the cDNA samples stored at -20˚C. 
2.10. Quantitative real-time polymerase chain reaction (qPCR) 
Realtime qPCR was performed using the LightCycler 96 system (Roche Applied Science, SA) 
according to the manufacturer’s instructions. The reaction master mix was prepared as follows per 
sample: 0.5 µM forward and reverse primers, 5 µL SYBR Green (Kapa SYBR Fast qPCR master 
mix; Roche Applied science, SA) and 2 µL sterile PCR-grade water. For the reaction in the 
LightCycler Multiwell plates (Roche Diagnostics (Pty) Ltd, SA), a volume of 9 μl of the master mix 
was added to each well, and 1 µl of either cDNA or the sterile PCR-grade water (non-template 
negative control). The details of the forward and reverse primers used in this study are shown in Table 
2.3. A melting curve analyses was performed to confirm the presence of a single amplicon 
(Addendum B, Figure B3), while the amplicon size was confirmed by agarose gel electrophoresis 
(Addendum B, Figure B4). GAPDH was used as the internal control, and the relative transcript levels 
of the target genes was normalised to the relative transcript levels of this gene. Target genes were 
quantified using the mathematical equation described by Pfaffl (Pfaffl, 2001). 
 




Table 2.3 Details of primers used for quantitative analysis of gene expression. 










203 57 1.83 
(Chottanapund et 
al., 2013) GTCGACCCCGCTCCTTTT Reverse 
Bax 
GAGAGGTCTTTTTCCGAGTG Forward 








307 60 2 
(Ishibashi et al., 
2003) TCCACCACCCTGTTGCTGTA Reverse 
 
2.11. Data and Statistical Analysis  
Visual representation and statistical analysis were conducted using the GraphPad Prism® v 5.00 
software package, for Windows (GraphPad Software, USA). For Western Blot analysis, one-way 
ANOVA with Bonferroni’s (compare all pairs of columns) post-test was used. One-way ANOVA 
with Newman-Keuls (compare all pairs of columns) post-test was used for MTT assays and qPCR 
experiments. For apoptosis and zymography assays, one-way ANOVA with either Dunnett’s 
(compare all columns vs control column) or Bonferroni’s (compare all pairs of columns) post-test 
were used for statistical analyses. For all assays, data with two or more data sets were analysed using 
two-way ANOVA with Bonferroni’s post-test. Statistical significance were indicated either by letters, 
with values statistically different being assigned different letters, or by *, ** or ***, to indicate 
p<0.05, p<0.01 or p<0.001, while no statistical significance (ns) indicates p>0.05. The error bars 
indicate the standard error of the mean (SEM) of three independent experiments, except for the 
transwell invasion assay where only a single experiment was performed.  
 
  


















3.1. All progestogens downregulated the expression of both PR-isoforms in T47D 
breast cancer cells, while the effects were not influenced by IL-6 or TNFα. 
Steroid hormones mediate their physiological effects by binding to steroid receptors, most of which 
have been implicated in breast cancer pathogenesis (Birrell et al., 1998; Conzen, 2008; Peters et al., 
2009; Thomas and Gustafsson, 2015; Wellberg et al., 2017; McFall et al., 2018). It is well known 
that the cognate hormone of a steroid receptor can regulate its expression (Kathryn B. Horwitz and 
Mcguire, 1978; Dong et al., 1988; Y. Zhang et al., 2009; Chang et al., 2013). This study investigated 
whether the natural female hormones, E2 and P4, as well as selected progestins (MPA, NET-A, LNG, 
GES, DRSP and NoMAC) could also influence the expression levels of steroid receptors. Moreover, 
the effects of these hormones on steroid receptor expression, in the absence and presence of either 
IL-6 or TNFα, were also investigated. This investigation was done in the T47D breast cancer cell line 
as it endogenously expresses high levels of the PR isoforms, the ER subtypes, AR and GR (Nardulli 
and katzenelenbogen, 1988; Satrorius et al., 1994; Jacobsen and Horwitz, 2012). Western blot 
analyses were performed with lysates of the T47D breast cancer cell line treated with either 0.1% 
(v/v) EtOH or 100 nM of the hormones in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml 
TNFα. These specific concentrations of IL-6 and TNFα were previously used in studies investigating 
effects of these cytokines on breast cancer cell proliferation (Chiu et al., 1996; Rubio et al., 2006; 
Sasser et al., 2007).  
As the test compounds in this study are primarily PR ligands, we firstly investigated the effects of the 
test compounds on the expression levels of the PR isoforms. A representative western blot for both 
the PR isoforms is shown in Figure 3.1A. The quantification of the blot shows that promegestone 
(R5020), a potent synthetic agonist for the PR, downregulated the expression of both PR-A and PR-
B (Figure 3.1B and D), while E2 caused an increase in the expression of both isoforms. Both these 
results are consistent with previous findings in MCF-7 and T47D breast cancer cell lines (Read et al., 
1988; Lauber et al., 2004; Tung et al., 2006; Chen et al., 2013). Interestingly, our results in the T47D 
breast cancer cell line show that all the progestogens decreased the expression of both the PR-
isoforms to the same extent, and neither IL-6 nor TNFα could modulate these effects (Figure 3.1C 
and E).  
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Figure 3.1 All the progestogens downregulated the expression of PR-A and PR-B in T47D breast cancer cells, and 
the effects were not influenced by IL-6 or TNFα. Total protein from the human T47D breast cancer cell line treated with 
either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones, in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα for 
24 hours, was harvested for western blotting. Steroid receptor expression was detected using antibodies specific for the 
progesterone receptor-A/B (PR-A/B) and GAPDH, and quantified using MYImage Analysis. (A) The western blot shown 
is representative of 3 independent experiments for PR-A and PR-B. One-way ANOVA with Bonferroni’s (compares all 
pairs of columns) post-test were used to compare the effects of the hormones on the expression of (B) PR-B and (D) PR-
A. Two-way ANOVA with Bonferroni’s post-test was used to compare the effects of hormones on the expression of (C) 
PR-B and (E) PR-A, in the absence and presence of IL-6 or TNFα. For the one-way ANOVA analysis, statistically 
significant differences are indicated by letters, with values statistically different being assigned different letters, while for 
two-way ANOVA statistically significant differences are indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; 
no statistical significance (ns) indicates p>0.05. 
3.2. Like E2, all the progestins downregulated the expression of both ER-subtypes, and 
the effects were not modulated by IL-6 or TNFα. 
It is well-known that some progestins can interact with other members of the steroid receptor family 
such as the AR, GR and ERα (Koubovec et al., 2005; Africander et al., 2014; Louw-du Toit et al., 
2017). Moreover, it has been shown that ERα is required for MPA-induced gene expression via the PR 
(Giulianelli et al., 2012), while progestin (R5020)-bound PR can modulate the transcriptional activity 
of ERα (Mohammed et al., 2015). 
Western blot analyses for ERα as well as the ERβ subtype were thus next performed using lysates of 
the T47D breast cancer cell line treated as in Section 3.1. As shown in Figure 3.2B, all hormones, 
except P4, decreased the expression of ERα, with all progestins decreasing ERα expression to a similar 
extent. Although all hormones decreased the expression of ERβ, P4, DRSP and NoMAC decreased 
expression to a lesser extent (Figure 3.2D). Consistent with the literature, E2, the cognate ligand for 
ERα and ERβ, downregulated the expression of both isoforms (Y. Zhang et al., 2009; Yeh et al., 2013). 
Neither IL-6 nor TNFα modulated the above-mentioned effects on ER protein expression levels (Figure 
3.2C and E). 
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Figure 3.2 All hormones, except P4, downregulated the expression of both ERα and ERβ in T47D cells, and the 
effects were not influenced by IL-6 or TNFα. Total protein from the human T47D breast cancer cell line treated with 
either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones, in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα for 
24 hours, was harvested for western blotting. Steroid receptor expression was detected using antibodies specific for ERα, 
ERβ and GAPDH, and quantified using MYImage Analysis. (A) The western blot shown is representative of 3 independent 
experiments for ERα and ERβ. One-way ANOVA with Bonferroni’s (compares all pairs of columns) post-test were used 
to compare the effects of the hormones on the expression of (B) ERα and (D) ERβ. Two-way ANOVA with Bonferroni’s 
post–test was used to compare the effects of hormones on the expression of (C) ERα and (E) ERβ, in the absence and 
presence of IL-6 or TNFα. For the one-way ANOVA analysis, statistically significant differences are indicated by letters, 
with values statistically different being assigned different letters, while for two-way ANOVA statistically significant 
differences are indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; no statistical significance (ns) indicates 
p>0.05. 
3.3. All progestogens and E2 downregulated the expression of the AR, but not the GR, 
and the effects were not modulated by IL-6 or TNFα. 
Next we investigated the effects of the progestins on the expression levels of the AR and GR as these 
receptors are also implicated in breast cancer pathogenesis and it is known that a number of progestins 
bind to these receptors (Koubovec et al., 2005; Africander et al., 2014; Louw-du Toit et al., 2017). 
Figure 3.3B shows that the synthetic androgen mibolerone (Mib) downregulates the expression of the 
AR, while all the progestogens decreased AR expression to the same extent as each other (Figure 3.3B). 
E2 also decreased the expression of the AR, albeit to a lesser extent. As expected, the synthetic 
glucocorticoid, dexamethasone (Dex), decreased the expression of the GR (Figure 3.3D) (Dong et al., 
1988; Burnstein& et al., 1990; Burnstein et al., 1994; Webster et al., 2001; Xue et al., 2014). None of 
the progestogens or E2 had a significant effect on GR expression levels in the T47D breast cancer cells 
compared to the vehicle (Figure 3.3D). Although IL-6 had no effect on the expression of either the AR 
(Figure 3.3C) or the GR (Figure 3.3E) in T47D breast cancer cells, GR protein expression was 
increased in response to TNFα (Figure 3.3E). The increased GR expression in response to TNFα, 
correlates with a study reporting that TNFα upregulated the expression of the GR in human cervical 
adenocarcinoma (HeLaS3) and human lymphoid (CEMC7) cells (Webster et al., 2001). Importantly, 
none of the effects of the hormones on steroid receptor expression were modulated by the addition of 
the pro-inflammatory mediators. 
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Figure 3.3 All hormones evaluated downregulated the expression of the AR, but not the GR in the T47D and the 
effects were not influenced by IL-6 or TNFα. However, TNFα on its own increased the expression of the GR. Total 
protein from the human T47D breast cancer cell line treated with either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones, 
in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα for 24 hours, was harvested for western blotting. Steroid 
receptor expression was detected using antibodies specific for the androgen receptor (AR), glucocorticoid receptor (GR) 
and GAPDH, and quantified using MYImage Analysis. (A) The western blot shown is representative of 3 independent 
experiments for AR and GR protein expression. One-way ANOVA with Bonferroni’s (compares all pairs of columns) post-
test were used to compare the effects of the hormones on the expression of (B) AR and (D) GR. Two-way ANOVA with 
Bonferroni’s post–test was used to compare the effects of hormones on the expression of (C) AR and (E) GR, in the absence 
and presence of IL-6 or TNFα. For the one-way ANOVA analysis, statistically significant differences are indicated by 
letters, with values statistically different being assigned different letters, while for two-way ANOVA statistically significant 
differences are indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; no statistical significance (ns) indicates 
p>0.05. 
3.4. Progestogens display differential effects on proliferation in both the T47D and 
MCF-7 BUS breast cancer cell lines. 
The evidence in the literature regarding the effects of the progestins on proliferation of breast cancer 
cells are contradictory, with effects appearing to be cell line-specific. For example, at least two studies 
show that MPA increases the proliferation of T47D breast cancer cells (Liang et al., 2006; Izzo et al., 
2014), while another study has shown that MPA has no effect on the proliferation of MCF-7 breast 
cancer cells (Catherino et al., 1993). NET-A, GES and LNG have been shown to increase the 
proliferation of MCF-7 breast cancer cells (Van den Burg et al., 1992; Schoonen et al., 1995; Franke 
and Vermes, 2003), but NET-A have been shown to inhibit proliferation of the T47D breast cancer cell 
line (Botella et al., 1994) suggesting cell-line specific effects. Thus, this study directly compared the 
effects of different progestins on the proliferation of both the T47D and MCF-7 BUS breast cancer cell 
lines. T47D cells were seeded at 1x104 cells per well while the MCF-7 BUS cells were serum-starved 
for one week before seeding at 5x103 cells per well. These cell numbers were previously optimised in 
the Africander laboratory. Both cell lines were treated for 72 hours with either 0.1% (v/v) EtOH 
(vehicle control), 100 nM E2 or progestogen. The medium was subsequently aspirated, and the cells 
retreated with the same hormones for a further 48 hours. Results in Figure 3.4A show that E2 increased 
the proliferation of the T47D breast cancer cell line, while all progestogens, except DRSP and NoMAC, 
increased proliferation of the T47D breast cancer cell line to a similar extent. Interestingly, P4, MPA, 
NET-A and GES differentially increased the proliferation of the MCF-7 BUS cell line, while LNG, 
DRSP and NoMAC had no effect on proliferation (Figure 3.4B). To confirm whether the effects of the 
progestins are indeed cell-specific, the data from Figure 3.4A and B were replotted and are shown in 
Figure 3.4C. The analysis shows that while E2, P4, MPA, NET-A and GES increase proliferation of 
both cell lines, the increase is significantly higher in the MCF-7 BUS cell line. Interestingly, neither 




DRSP or NoMAC influenced cell proliferation in either cell line. Surprisingly, LNG increased 
proliferation of only the T47D cells. 
 
Figure 3.4 E2 and the progestogens differentially regulate proliferation of the T47D and MCF-7 BUS breast cancer 
cell lines. (A) T47D and (B) MCF-7 BUS breast cancer cells were treated with either 0,1% (v/v) EtOH (vehicle) or 100 nM 
hormones for 72 hours. Thereafter, the cells were retreated with the same test compounds for 48 hours and cell proliferation 
quantified using the MTT cell viability assay. Proliferation is shown as fold proliferation with 0.1% EtOH (vehicle) set as 
1 and all other test compounds set relative to this. The result shown represents the average of three independent experiments 
performed in triplicate. One-way ANOVA with Newman-Keuls (compares all pairs of columns) post-test were used for 
statistical analysis. (C) Data of (A) and (B) were replotted as grouped data, and statistical analysis performed using two-
way ANOVA and Bonferroni’s post-test. Statistical significance is indicated by either letters, where values that differ 
significantly are assigned different letters, or using *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; no statistical 
significance (ns) indicates p>0.05.  
3.5. IL-6 had no effect on progestogen-induced proliferation of the T47D or MCF-7 
BUS breast cancer cell lines, while proliferation of the MCF-7 BUS breast cancer 
cells was significantly decreased by TNFα. 
Having shown that the progestins differentially regulate breast cancer cell proliferation, with some in 
a cell line-dependent manner, we next investigated whether these responses would be influenced by 
the inflammatory mediators, IL-6 and TNFα. The T47D and MCF-7 BUS breast cancer cell lines were 
thus treated with either 0.1% (v/v) EtOH or 100 nM of the hormones in the absence and presence of 5 
ng/ml IL-6 or 20 ng/ml TNFα.
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Figure 3.5 IL-6 did not modulate hormone-induced proliferation of the MCF-7 BUS or T47D breast cancer cell lines, 
while TNFα decreased proliferation in only the MCF-7 BUS cells. (A and C) T47D and (B and D) MCF-7 BUS breast 
cancer cells were treated with either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones in the absence and presence of 5 ng/ml 
IL-6 or 20 ng/ml TNFα for 72 hours. Thereafter, the cells were retreated with the same test compounds for 48 hours. 
Proliferation is shown as fold proliferation with 0.1% EtOH set as 1 and all other test compounds set relative to this. The 
result shown is the average of three independent experiments performed in triplicate. Two-way ANOVA with Bonferroni’s 
post–test was used for statistical analyses. Statistical significance is indicated by *, ** or ***, to indicate p<0.05, p<0.01 
or p<0.001; no statistical significance (ns) indicates p>0.05. 
Results showed that IL-6 did not modulate the progestogen-induced proliferation in either the T47D 
(Figure 3.5A) or MCF-7 BUS (Figure 3.5B) breast cancer cell lines. Although 20 ng/ml TNFα also had 
no effect on progestogen-induced proliferation of the T47D breast cancer cells (Figure 3.5C), it 
displayed anti-proliferative effects in the MCF-7 BUS breast cancer cells (Figure 3.5D). Consistent 
with these results, the real-time qPCR results in Figure 3.6 shows that both IL-6 and TNFα had no 
significant effect on the mRNA expression of Ki-67, a well-studied marker of proliferation 
(Klinkhammer-schalke, 2013; Dai et al., 2016; Mannell, 2016), in the T47D cells (Figure 3.6A), while 
its expression in the MCF-7 BUS cells was significantly decreased by TNFα (Figure 3.6B). Also in 
line with the proliferation assay (Figure 3.4), E2 and MPA upregulated Ki-67 expression in both cell 
lines (Tan et al., 2009; Wood et al., 2013; Holton et al., 2014). 
 
Figure 3.6 TNFα decreased the mRNA expression of Ki-67 in the MCF-7 BUS, but not the T47D, cell line. (A) T47D 
and (B) MCF-7 BUS breast cancer cells were treated with either 0.1% (v/v) EtOH, 5 ng/ml IL-6, 20 ng/ml TNFα, 100 nM 
E2 or MPA for 24 hours. Total RNA was isolated, cDNA synthesised and the mRNA expression levels of Ki-67 and 
GAPDH determined by qPCR. GAPDH was used as the internal standard and the ratio of Ki-67 mRNA/GAPDH mRNA 
of the treated samples were calculated relative to that of the vehicle. Results represent the average of three independent 
experiments. One-way ANOVA with Newman-Keuls (compare all pairs of columns) post-test were used for statistical 
analysis. Statistical significance is indicated by letters, where values that differ significantly are assigned different letters. 




3.6. IL-6 and the hormones had no effect on apoptosis in either the T47D or MCF-7 
BUS cell line. TNFα on the other hand, induced apoptosis in the MCF-7 BUS cell 
line, but not in the T47D cell line. 
It has been shown that TNFα promotes apoptosis in MCF-7 cells (Simstein et al., 2003), but not in 
T47D cells (Nojek et al., 2006). Having shown that TNFα decreases the viability of the MCF-7 BUS 
cells, but not the T47D cells (Figure 3.5), we hypothesised that this decrease was due to TNFα inducing 
apoptosis of the MCF-7 BUS cells. We thus treated the T47D and MCF-7 BUS breast cancer cell lines 
with either 5 ng/ml IL-6 or 20 ng/ml TNFα, and measured apoptosis using the Caspase-Glo 3/7 
apoptosis detection assay kit (Promega, Anatech, SA). First, the optimal cell density was determined 
to be 1x103 cells per well for both cell lines (Addendum B, Figure B5). The treatment time for these 
experiments were based on the fact that Mooney et al. showed that the mechanism of apoptosis differs 
between the T47D and MCF-7 cell lines, with the MCF-7 cell line being an early apoptotic cell line, 
as compared to the T47D cell line (Mooney et al., 2002). Thus, we treated the T47D breast cancer cells 
with test compound for a much longer time period (24 hours) than the MCF-7 BUS cells (6 hours). The 
results in Figure 3.7B confirms that TNFα induced apoptosis in the MCF-7 BUS cells, but not in the 
T47D cells (Figure 3.7A). IL-6 on the other hand, had no effect on apoptosis in either cell line (Figure 
3.7). The lack of apoptosis induction was not due to the assay not working in the T47D breast cancer 
cells, as Tamoxifen, a known inducer of apoptosis (Li et al., 2008; Vivian et al., 2011), induced 
apoptosis in these cells (Addendum B, Figure B5).  
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Figure 3.7 Only TNFα induced apoptosis in the MCF-7 BUS breast cancer cell line, while neither IL-6, nor TNFα 
induced apoptosis in the T47D breast cancer cell line. (A) T47D and (B) MCF-7 BUS breast cancer cells were treated 
with 0.1% (v/v) EtOH (vehicle), 5 ng/ml IL-6 or 20 ng/ml TNFα for 24 and 6 hours, respectively. The Caspase-Glo 3/7 
luminescent assay was used to determine caspase-3 and 7 activities, as a measure of apoptosis. Results are expressed as the 
fold caspase 3/7 activity relative to EtOH (vehicle) set as 1 and represent the average of three independent experiments 
performed in triplicate. One-way ANOVA with Dunnett’s (compare all columns vs. control column) post-test were used 
for statistical analyses. Statistical significant differences are indicated by *, ** or ***, to indicate p<0.05, p<0.01 or 
p<0.001; no statistical significance (ns) indicates p>0.05. 
 
In contrast to the above-mentioned effects using the caspase kit, both IL-6 and TNFα increased the 
mRNA expression of the pro-apoptotic Bax gene in the T47D cells (Figure 3.8A), while having no 
effect on Bax expression in the MCF-7 BUS cells (Figure 3.8C). Both TNFα and IL-6 also upregulated 
the mRNA expression of the anti-apoptotic Bcl-2 gene in T47D cells (Figure 3.8B), while neither IL-
6 nor TNFα had any effect on Bcl-2 in MCF-7 BUS cells (Figure 3.8D). 
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Figure 3.8 IL-6 and TNFα significantly upregulated the mRNA expression of both the pro-apoptotic, Bax, and anti-
apoptotic, Bcl-2, gene in only the T47D cells, while having no effect on the MCF-7 BUS cells. (A and B) T47D and (C 
and D) MCF-7 BUS cells were treated with either 0.1% (v/v) EtOH, 5 ng/ml IL-6, 20 ng/ml TNFα, 100 nM E2 or MPA for 
24 hours. Total RNA was isolated, cDNA synthesised and mRNA expression levels of Bax, Bcl-2 and GAPDH were 
determined by qPCR. GAPDH was used as the internal standard and the ratio of Bax mRNA/GAPDH mRNA of the treated 
samples were calculated relative to EtOH. Results represent the average of three independent experiments. One-way 
ANOVA with Newman-Keuls (compare all pairs of columns) post-test were used for statistical analyses. Statistical 
significance is indicated by letters, where values that differ significantly are assigned different letters. 
Having shown the effects of IL-6 and TNFα on both proliferation and apoptosis, and that E2 and the 
progestogens differentially regulate breast cancer cell proliferation, we next investigated the effects of 
these hormones on apoptosis, and whether the effects are influenced by IL-6 or TNFα. Investigating 
the effects on both proliferation and apoptosis is important as these processes are opposing 
determinants of breast cancer cell survival and growth (Evan and Vousden, 2001). Results from the 
Caspase-Glo 3/7 assay showed that none of the hormones, in the absence or presence of IL-6, induced 
apoptosis in either the T47D (Figure 3.9A and C) or MCF-7 BUS (Figure 3.9B and D) breast cancer 
cell lines. Similarly, apoptosis was not induced in T47D cells treated with both hormone and TNFα 
(Figure 3.9C). Although an increase in apoptosis was observed in MCF-7 BUS cells treated with 
hormone and TNFα (Figure 3.9D), this was likely due to the increase in apoptosis observed for TNFα 
only.  
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Figure 3.9 Neither E2 nor the progestogens induced apoptosis in T47D and MCF-7 BUS breast cancer cell lines. (A 
and C) T47D and (B and D) MCF-7 BUS breast cancer cells were treated with 0.1% (v/v) EtOH (vehicle) or 100 nM 
hormones in the (A and B) absence and (C and D) presence of 5 ng/ml IL-6 or 20 ng/ml TNFα for 24 and 6 hours, 
respectively. The Caspase-Glo 3/7 luminescent assay was used to determine the caspase-3 and 7 activities, as a measure of 
apoptosis. Results are expressed as fold caspase 3/7 activity relative to EtOH (vehicle) set as 1 and represent the average 
of three independent experiments performed in triplicate. One-way ANOVA (A and B) and two-way ANOVA (C and D) 
with Bonferroni’s post–test was used for statistical analyses. Statistically significant differences are indicated by *, ** or 
***, to indicate p<0.05, p<0.01 or p<0.001; no statistical significance (ns) indicates p>0.05. 
3.7. The effect of the hormones and the inflammatory mediators on the migration of 
T47D breast cancer cells 
In addition to the uncontrolled cell growth of cancer cells, these cells can also metastasize by a multi-
step process that includes migration and invasion of cancer cells (Hanahan and Weinberg, 2011; Martin 
et al., 2013). Having shown that the selected progestins differentially increased breast cancer cell 
proliferation (Figure 3.4), we next investigated their effects on the migration and invasion of the breast 
cancer cells. Considering that IL-6 and TNFα are known to enhance the migration of breast cancer 
cells (Wolczyk et al., 2016; Gallo et al., 2018), we also investigated effects of different concentrations 
of these inflammatory mediators on migration, as well as whether any hormone-mediated effects would 
be influenced in their presence. As we had previously shown that TNFα is cytotoxic to the MCF-7 
BUS cells (Figure 3.5D), via the induction of apoptosis (Figure 3.7B), migration was evaluated only 
in the T47D breast cancer cell line. The frequently used wound scratch assay was used to measure the 
migration of T47D cells treated with the hormones, the inflammatory mediators or combinations of 
these over a 72-hour time period.  
3.7.1. All concentrations of IL-6 evaluated similarly increased migration of the 
T47D breast cancer cells, whereas 20 ng/ml TNFα showed the highest increase in 
migration of this cell line. 
First, we wanted to confirm previous reports that IL-6 and TNFα increase migration of breast cancer 
cells (Badache and Hynes, 2001; Wolczyk et al., 2016; Gallo et al., 2018). T47D cells were thus 
incubated with increasing concentrations of IL-6 (5, 20, 50 and 100 ng/ml) and TNFα (2, 20 and 200 
ng/ml). Figure 3.10A and Figure 3.11A show photographs of the wounds captured at 0, 24, 48 and 72 
hours using an inverted microscope, while Figure 3.10B-D and Figure 3.11B-D show the quantification 
of these photographs. Figure 3.10B and Figure 3.11B show the increase in migration over time in the 
presence of different concentrations of IL-6 and TNFα, respectively. The data in Figure 3.10B and 
Figure 3.11B were replotted as grouped bar graphs to show the statistical significance of the increase 
in migration over time in response to a specific concentration of IL-6 and TNFα (Figure 3.10C and 




Figure 3.11C), and the statistical significance of the effects of the different concentrations of IL-6 and 
TNFα on migration at a specific time point (Figure 3.10D, and Figure 3.11D). Taken together, these 
results show that migration of the T47D breast cancer cells was increased in a time-dependent manner 
by all concentrations of IL-6 (Figure 3.10B and C). Surprisingly, all concentrations of IL-6 increased 
the migration of the T47D cells to similar extent at 24, 48 and 72 hours (Figure 3.10D). Thus, 5 ng/ml 
IL-6 was used in subsequent assays evaluating migration, as this was also the concentration used in the 
proliferation and apoptosis assays. Figure 3.11C shows that all concentrations of TNFα significantly 
increased the migration of T47D breast cancer cells at 72 hours, while Figure 3.11D shows that only 
20 ng/ml TNFα significantly increased migration of T47D breast cancer cells at all time-points. 
Interestingly, 20 ng/ml TNFα was also the concentration used in the MTT and apoptosis assays.  
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Figure 3.10 The increase in migration of T47D breast cancer cells in response to IL-6 was time but not concentration 
dependent. T47D breast cancer cells were treated with either 0.1% (v/v) EtOH (vehicle) or 5, 20, 50 and 100 ng/ml IL-6. 
A wound scratch assay was used to measure the migration of the cells in response to treatment. Photographs of the wound 
were captured at t=0 (0 hours), 24, 48 and 72 hours using an inverted microscope and representative images are shown in 
(A). Image J was used to measure the width of the wound at each time point and the relative percentage (%) migration 
relative to the initial wound area was calculated (B). The data in (B) was replotted as bar graphs and show the statistical 
significance of the (C) time-dependent increase in migration in response to IL-6, and (D) migration in response to increasing 
concentrations of IL-6 at specific time points. Results represent the average of three independent experiments. Two-way 
ANOVA with Bonferroni’s (compares each column to all other columns) post-test were used for statistical analysis. 
Statistical significance is indicated either by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; no statistical significance 
(ns) indicates p>0.05, or by letters, with values statistically different being assigned different letters. 
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Figure 3.11 Migration of T47D breast cancer cells in response to TNFα was optimal at 20 ng/ml at all time points 
evaluated. T47D breast cancer cells were treated with either 0.1% (v/v) EtOH (vehicle) or 2, 20, and 200 ng/ml TNFα. A 
wound scratch assay was used to measure the migration of the cells in response to treatment. Photographs of the wound 
were captured at t=0 (0 hours), 24, 48 and 72 hours using an inverted microscope and representative images are shown in 
(A). Image J was used to measure the width of the wound at each time point and the relative percentage (%) migration 
relative to the initial wound area could be calculated. (B). The data in (B) was replotted as bar graphs and show the statistical 
significance of the (C) time-dependent increase in migration in response to TNFα, and (D) migration in response to 
increasing concentrations of TNFα at specific time points. Results represent the average of three independent experiments. 
Two-way ANOVA with Bonferroni’s (compares each column to all other columns) post-test were used for statistical 
analysis. Statistical significance is either indicated *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; no statistical 
significance (ns) indicates p>0.05, or by letters, with values statistically different being assigned different letters. 
3.7.2. Unlike P4, E2 and all the progestins increased the migration of T47D cells. 
Results for the evaluation of the effects of E2 and the progestogens on the migration of the T47D breast 
cancer cells are shown in Figure 3.12. Photographs of the wounds captured at 0, 24, 48 and 72 hours 
are shown in Figure 3.12A. Quantification of photographs are shown in Figure 3.12B and results are 
represented as % migration over time. The same data in Figure 3.12B was replotted in Figure 3.12C-E 
to show the statistical significance of the migration in response to the hormones at specific time points. 
The results show that migration of T47D breast cancer cells in response to E2 and all the progestins 
was already evident after 24 hours (Figure 3.12C), and all hormones, except P4, increased migration of 
these cells to the same extent at 24, 48 and 72 hours (Figure 3.12C to E). P4 was the only hormone that 
had no significant effect on the migration of T47D breast cancer cells over a time-period of 72 hours. 
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Figure 3.12 All hormones evaluated, except P4, increased the migration of T47D cells to the same extent. T47D breast 
cancer cells were treated with either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones. A wound scratch assay was used to 
measure the % migration of the cells in response to treatment. Photographs of the wound were captured at t=0 (0 hours), 
24, 48 and 72 hours using an inverted microscope and representative images are shown in (A). Image J was used to measure 
the width of the wound at each time point and the relative percentage migration relative to the initial wound area was 
calculated and (B) shows percentage migration over time. The data in (B) was replotted as bar graphs in (C, D and E) and 
show the statistical significance of the migration in response to the hormones at 24 hours, 48 hours and 72 hours, 
respectively. Results represent the average of three independent experiments. Two-way ANOVA with Bonferroni’s 
(compare all pairs of columns) post-test were used for statistical analyses. Statistical significance is indicated with letters, 
with values statistically different being assigned different letters (C-E).  
3.7.3. Neither of the two inflammatory mediators modulated the effects of the 
hormones on migration of the T47D breast cancer cell line. 
Having shown that both IL-6 and TNFα (Figure 3.10 and Figure 3.11), as well as the progestins and E2 
(Figure 3.12), increased migration of the T47D breast cancer cell line, we next evaluated migration in 
the presence of a combination of IL-6 or TNFα with these hormones. T47D breast cancer cells were 
treated with either 0.1% (v/v) EtOH or 100 nM hormones in the absence and presence of either 5 ng/ml 
IL-6 (Figure 3.13) or 20 ng/ml TNFα (Figure 3.14). Representative images for T47D cells treated with 
the hormones in the absence and presence of IL-6 or TNFα are shown in Figure 3.13A and Figure 
3.14A, respectively. As results were similar at all the time points, the quantification of the effects of 
the hormones in combination with either IL-6 (Figure 3.13B) or TNFα (Figure 3.14B) are shown only 
for the 72 hour time point. Interestingly, neither IL-6 (Figure 3.13B) nor TNFα (Figure 3.14B) could 
modulate the effects of the hormones on the migration of the T47D breast cancer cell line. 
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Figure 3.13 IL-6 did not modulate the hormone-induced increase in migration of the T47D breast cancer cells. T47D 
cells were treated with either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones in the absence and presence of 5 ng/ml IL-
6. A wound scratch assay was used to measure the percentage (%) migration of the cells in response to treatment. 
Photographs of the wound were captured at t=0 (0 hours), 24, 48 and 72 hours using an inverted microscope and 
representative images are shown in (A). Image J was used to measure the width of the wound at each time point and the 
relative percentage migration relative to the initial wound area was calculated. A representative result of the average of 
three independent experiments at 72 hours is shown in (B). Two-way ANOVA with Bonferroni’s (compare all pairs of 
columns) post–test was used for statistical analyses. Statistical significance is indicated by *, ** or ***, to indicate p<0.05, 
p<0.01 or p<0.001; no statistical significance (ns) indicates p>0.05.  
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Figure 3.14 TNFα did not modulate the hormone-induced increase in migration of the T47D breast cancer cells. 
T47D cells were treated with either 0.1% (v/v) EtOH (vehicle) or 100 nM hormones in the absence and presence of 20 
ng/ml TNFα. A wound scratch assay was used to measure the percentage (%) migration of the cells in response to treatment. 
Photographs of the wound were captured at t=0 (0 hours), 24, 48 and 72 hours using an inverted microscope and 
representative images are shown in (A). Image J was used to measure the width of the wound at each time point and the 
relative percentage migration relative to the initial wound area was calculated. A representative result of the average of 
three independent experiments at 72 hours is shown in (B). Two-way ANOVA with Bonferroni’s (compare all pairs of 
columns) post–test was used for statistical analyses. Statistical significance is indicated by *, ** or ***, to indicate p<0.05, 
p<0.01 or p<0.001; no statistical significance (ns) indicates p>0.05.  
3.8. None of the hormones or inflammatory mediators regulated MMP-2 expression in 
the T47D breast cancer cell line. 
Having shown that IL-6 (Figure 3.10) and TNFα (Figure 3.11), as well as E2 and the progestins (Figure 
3.12), increased the migration of T47D breast cancer cells, we next investigated the effects of these 
test compounds on invasion. It has previously been shown that one of the possible mechanisms by 
which IL-6 and/or TNFα promote invasion of breast cancer cells is by increasing extracellular matrix 
metalloproteases (MMPs) in tumours (Hagemann et al., 2005; Ibrahim et al., 2016). MMP-2 and 
MMP-9 are gelatinases that play key roles in degrading extracellular matrices and promoting tumour 
invasion and metastasis (Toth and Fridman, 2001; Wolczyk et al., 2016). A gelatin zymography assay 
was used to evaluate the secretion of MMP-2 and MMP-9 in T47D breast cancer cells (Toth and 
Fridman, 2001) treated with either 0.1% (v/v) EtOH or 100 nM hormones in the absence and presence 
of 5 ng/ml IL-6 or 20 ng/ml TNFα for 24 hours. Although both MMP-9 and MMP-2 could be detected 
(Figure 3.15A), the bands for MMP-9 were too feint to be quantified. Quantification of MMP-2 showed 
that neither IL-6, TNFα (Figure 3.15C), the selected hormones (Figure 3.15D), nor combinations of 
these (Figure 3.15E), had any effect on MMP-2 expression levels in the T47D breast cancer cell line.  
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Figure 3.15 Gelatin zymography showing that none of the hormones or the inflammatory mediators influenced 
MMP-2 expression in the T47D breast cancer cell line. Supernatants from T47D cells treated with either 0.1% (v/v) 
EtOH (vehicle) or 100 nM hormones in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα for 24 hours was 
harvested for gelatin zymography. Representative gels of three independent experiments indicating (A) MMP-9 at 84 kDa 
and MMP-2at 62 kDa and (B) the total protein loaded, are shown. Densitometric analyses of the bands were done using 
Image J (Hu and Beeton, 2010). One-way ANOVA with Dunnett’s (compare all columns to the vehicle) and two-way 
ANOVA with Bonferroni’s (compare all pairs of columns) post–tests were used for statistical analyses. Statistical 
significance is indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001; no statistical significance (ns) indicates 
p>0.05.  
3.9. TNFα inhibited the MPA and DRSP-induced increase in invasion of the MDA-
MB-231 breast cancer cells. 
As no significant increase in the MMP expression of the T47D breast cancer cell line was seen, the 
effects of the test compounds on invasion was next evaluated using the Boyden-chamber transwell 
invasion assay as described in Section 2. After two failed attempts in the T47D breast cancer cell line, 
and one in the MCF-7 BUS cell line, we questioned whether this was due to a sub-optimal technique 
or whether it was due to the specific cell lines used. In terms of the latter, the T47D and MCF-7 breast 
cancer cell lines are known to be less invasive than the MDA-MB-231 TNBC cell line (Gordon et al., 
2003; Sarnataro et al., 2006; Sun et al., 2016). For this reason, the highly invasive MDA-MB-231 
breast cancer cell line was next treated with the older first-generation progestin, MPA, and the newer 
fourth generation progestin, DRSP, in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα. 
Figure 3.16A shows confocal images of the cells on the filter membranes. The images could not be 
quantified due to the high proportion of invading cells, and thus quantification was achieved by 
dissolving the crystal violet stained cells in 33% glacial acetic acid and measuring the absorbance at 
590 nm as previously described (Liu et al., 2016). The relative absorbance values (Figure 3.16B) 
were plotted as fold invasion relative to the vehicle control set as 1 (Figure 3.16C). Results show that 
invasion of this cell line appears to be increased by MPA, DRSP, and IL-6, while the TNFα in the 
absence and presence of the hormones appear to decrease invasion. Interestingly, IL-6 also appears 
to decrease the effect of DRSP on invasion of the MDA-MB-231 breast cancer cell line, while the 
effect of MPA on invasion is unchanged in the presence of IL-6. However, it should be noted these 
results were from a single experiment, and thus no definitive conclusions can be drawn at this time. 





Figure 3.16 MPA, DRSP, and IL-6 increased the invasion of MDA-MB-231 breast cancer cells, while TNFα 
decreased invasion in the absence and presence of the progestins. The MDA-MB-231 breast cancer cells were treated 
with either 0.1% EtOH (control), 100 nM MPA or DRSP in the absence and presence of 5 ng/ml IL-6 or 20 ng/ml TNFα 
and cell invasion assayed with the matrigel invasion assay. (A) Representative confocal images of the invading cells on 
the membranes are shown, as well as the colorimetric quantification of the cells on the membrane (B and C). (B) The 
absorbance readings at 590 nm are tabulated and (C) the results, expressed as fold invasion relative to EtOH (vehicle) set 
as 1, are plotted. Results represent a single experiment.  
  













DISCUSSION AND CONCLUSIONS 
  





Breast cancer is the most prevalent cancer in women (Gordon et al., 2003; Sarnataro et al., 2006; 
MacCiò et al., 2009; Sun et al., 2016). Numerous risk factors contribute to breast cancer development 
and progression such as progestins used in menopausal HT and contraception, as well as being 
overweight or obese (Rossouw et al., 2002; Million Women Study Collaborators, 2003; Fournier et 
al., 2005; Iyengar et al., 2013; Zahid et al., 2018). Although there is a tendency to group effects of 
progestins as a class, it is important to note that a diverse range of progestins are clinically used and 
that not all progestins have been investigated for an association with increased breast cancer risk. 
Progestins were designed to exert biological effects similar to P4 by binding to the PR. However, 
some progestins are able to bind to multiple steroid receptors which may lead to off-target effects 
(Guerra et al., 2013; Stanczyk et al., 2013; Africander et al., 2014). It is well recognised that 
hormones and steroid receptors play important roles in breast cancer development and progression 
(Conzen, 2008). For example, ERα causes E2-mediated cell proliferation (Ali and Coombes, 2000; 
Chang et al., 2006; Williams et al., 2008; Cleary and Grossmann, 2009), while ERβ antagonises ERα-
mediated cell proliferation (Kuiper et al., 1996; Barkhem et al., 1998; Gustafsson, 1999; Lazennec et 
al., 2001; Platet et al., 2004; Ström et al., 2004). This suggests that ERβ is associated with good 
prognosis when co-expressed with ERα (Leygue and Murphy, 2013). Emerging evidence has also 
highlighted roles for the AR and GR, and show that whether these receptors are associated with either 
good or bad prognosis is dependent on whether ERα is expressed or not (Hopp et al., 2004; Doane et 
al., 2006; Hu et al., 2011; Diep et al., 2015; McFall et al., 2018). Similarly, progestin-bound PR has 
been shown to form a complex with ERα, and redirects ERα chromatin binding, leading to the 
expression of genes that are associated with a favourable outcome in ER+ breast cancer (Mohammed 
et al., 2015), whereas in ER- breast cancer, the PR causes cell proliferation (Thomas and Gustafsson, 
2015). The ratio of PR-A:PR-B is also upregulated in breast cancer which is associated with a poor 
prognosis and increased invasiveness of breast cancer (Hopp et al., 2004; Diep et al., 2015; McFall 
et al., 2018). 
In terms of the obesity risk factor, growing evidence suggests that excessive production of pro-
inflammatory cytokines such as IL-6 and TNFα, may be one of the mechanisms by which obesity 
contributes to breast cancer development and progression (Cole, 2009; MacCiò and Madeddu, 2011). 
The exact mechanism by which IL-6 and TNFα cause increased breast cancer risk is still poorly 
understood. It has however been suggested that these cytokines increase aromatase expression and 
activity, and thus estrogen signalling, as well as enhance tumour growth and metastasis (Purohit et 
al., 1995, 2002; MacCiò and Madeddu, 2011; Morris et al., 2012). Whether other mechanisms, such 
as the disruption of steroid receptor levels, may also be involved, is not known. Considering that the 




incidence of obesity and its associated risk factors continues to grow (Iyengar et al., 2013; Zahid et 
al., 2018), and that progestins are widely used in HT, it is crucial to understand whether the 
combination of these risk factors would further increase breast cancer risk. In the light of the above, 
we thus investigated the effects of selected progestins relative to the natural female hormones, in the 
absence and presence of the inflammatory mediators, IL-6 and TNFα, on steroid receptor expression 
in breast cancer cells, as well as on specific hallmarks of cancer cells. These included the growth 
(proliferation) and survival (apoptosis), as well as the migration and invasion of breast cancer cell 
lines (Hanahan et al., 2000; Hanahan and Weinberg, 2011). 
4.2. E2 and the progestogens differentially downregulated the expression of all steroid 
receptors, except the GR, in T47D breast cancer cells.  
Steroid hormones mediate their effects by binding to steroid receptors (Xu and O’Malley, 2002), 
which all play a role in breast cancer pathogenesis. Thus, we evaluated the effects of the natural 
female hormones, E2 and P4, as well as selected progestins used in menopausal HT and contraception, 
on the expression of the PR-isoforms, ER-subtypes, the AR and GR. The T47D breast cancer cell line 
was used as a model system as it endogenously expresses all these steroid receptors (Nardulli & 
Katzenelenbogen 1988; Satrorius et al. 1994; Jacobsen & Horwitz 2012), and all results are 
summarised in Table 4.1. Western blot analyses confirmed the well-established fact that the cognate 
ligand or synthetic analogues thereof, decrease the expression of the PR, ER and GR (Figure 3.1-
Figure 3.3) (Dong et al. 1988; Read et al. 1988; Zhang et al. 2009; Yeh et al. 2013). Results from 
this study showed that AR expression was decreased in response to the synthetic androgen, Mib 
(Figure 3.3B). This was surprising as it is has been shown that Mib and the natural androgen, DHT, 
increase AR protein expression in LNCaP prostate cancer and MDA-MB-453 breast cancer cell lines 
(Krongrad et al., 1991; Lee and Chang, 2003; Moore et al., 2006; Guo et al., 2007; Wang et al., 
2009). A possible reason for the discrepancy between our results and that in the literature, may be 
due the fact that LNCaP and MDA-MB-453 cell lines contain a mutant AR (Taplin et al., 1995; Yeap 
et al., 1999; Moore et al., 2012), while the wild-type AR is expressed in the T47D breast cancer cell 
line. The mutation in the AR found in the LNCaP and MDA-MB-453 cells are single point mutations 
in the ligand binding domain (Yeap et al., 1999; Moore et al., 2012). Given that a ligand induces 
conformational changes in a steroid receptor upon ligand binding (Lee and Chang, 2003), it may be 
possible that the androgens induce different conformations in the wild-type AR as compared to the 
mutant AR, which may result in degradation of the wild-type AR, but stabilisation of the mutant AR. 
When investigating the effects of E2 and the progestogens on the expression of these receptors, we 
show that the progestogens similarly decreased the expression of the AR and both PR-isoforms 




(Figure 3.1 and 3.3). Considering that high affinity PR agonists, like R5020 and P4, are known to 
decrease PR expression (Read et al., 1988), it was not completely surprising that the progestins, 
designed to have agonist activity via the PR, did the same. Given that the PR has been shown to be 
associated with a favourable outcome in ER+ breast cancer (Mohammed et al., 2015), a decrease in 
PR expression may lead to ERα chromatin binding and gene expression profiles that enhance 
tumourigenicity, thus resulting in a poor prognosis. Furthermore, our results showing that E2 
upregulates the expression of both PR-isoforms is also consistent with the well accepted fact that the 
PR is a classical target gene for the ER in breast cancer cells (Kastner et al., 1990; Chen et al., 2013). 
In terms of the AR, it is known that all the progestogens evaluated in this study bind to the AR, with 
MPA, NET-A, LNG and GES displaying agonist properties similar to DHT, while DRSP and 
NoMAC display antagonist properties (Louw-du Toit et al., 2017). It has been shown that AR 
agonists increase AR expression, while antagonists decrease its expression (Zhu et al., 2000; 
Rathkopf and Scher, 2013). It was thus surprising that all progestins similarly decreased the 
expression of the AR in this study (Figure 3.3B). E2 also decreased the expression of the AR, albeit 
to a lesser extent than the progestogens. This is in agreement with at least one study showing that E2 
significantly downregulates AR protein levels in T47D breast cancer cells (Ariazi et al., 2007). In 
ER+ breast cancer, activation of the AR is associated with a good prognosis as it can inhibit ERα 
signalling, and decrease breast cancer cell proliferation by increasing ERβ expression (Lanzino et al., 
2005; Peters et al., 2009; Rizza et al., 2014). In light of this, the result showing that all progestogens 
decreased the expression of the AR in this ER+ breast cancer cell line, may suggest an unfavourable 
outcome in terms of breast cancer. 
All the progestins decreased the expression of both ERα and ERβ, albeit to different extents, while 
P4 surprisingly had no effect on ERα expression, but decreased ERβ expression (Figure 3.2B and D). 
These results were surprising, as none of the progestogens can bind to ERβ, while only NET-A, LNG 
and GES can bind to ERα (Louw-du Toit et al., 2017). This suggests that the effects of MPA, DRSP 
and NoMAC on ERα expression, and P4 and all the progestins on ERβ expression, does not occur via 
a mechanism involving binding of the progestogens to ERα or ERβ, but rather via an indirect 
mechanism. It has been shown that crosstalk exists between ERα and the PR (Giulianelli et al., 2012; 
Daniel et al., 2015), and that progestin-bound PR can regulate the transcriptional activity of ERα 
(Mohammed et al., 2015). Given that the T47D breast cancer cells also express the PR, it may be 
possible that the progestin-induced effects on ER protein expression are in fact due to crosstalk 
between the progestin-bound PR and the ER subtypes. ERα-PR crosstalk in the presence of R5020 
and P4 has recently been reported to be associated with a good prognosis in terms of breast cancer 
(Mohammed et al., 2015). However, more studies investigating possible crosstalk between ERβ and 




the PR are lacking. Considering our results which indicates that progestins can decrease the 
expression of both ERα and ERβ, and knowing that ERβ plays an important role in antagonising ERα-
mediated proliferation in breast cancer cells, such investigations are crucial.  
In terms of the effects of E2 and the progestogens on GR expression, none of these hormones altered 
GR expression levels in the T47D breast cancer cells (Figure 3.3D), unlike the GR agonist Dex. 
Although, P4, MPA and GES are known partial agonists for the GR (Koubovec et al., 2005; Hapgood 
et al., 2013), a number of studies have previously shown that P4 and MPA do not modulate GR levels 
(Ronacher et al. 2009; Avenant et al. 2010; Nicolette Verhoog, University of Cape Town, PhD 
Thesis, 2010; Renate Louw-du Toit, Stellenbosch University, PhD Thesis, 2013).These studies also 
showed that NET-A, which has GR antagonist properties, does not influence GR levels. In agreement 
with our results, at least one other study reported that E2 has no effect on GR protein levels (Yong 
Zhang et al., 2009). In contrast, two other studies have shown that E2 causes a decrease in GR protein 
levels (Krishnan et al., 2001; Kinyamu and Archer, 2003). As with most other steroid receptors, the 
function of the GR in breast cancer depends on whether it is expressed in the absence or presence of 
ERα (Pan et al., 2011). When the GR is co-expressed with ERα, it is associated with a good prognosis 
in terms of breast cancer, while in the absence of ERα, this steroid receptor is associated with an 
unfavourable outcome (Pan et al., 2011). The fact that we show no effects on GR expression with E2 
and the progestogens suggests that the GR will be able to be activated by glucocorticoids, which 
suggests a favourable outcome in terms of ER+ breast cancer. 
Table 4.1 Summary of the effects of E2, the progestogens and the inflammatory mediators on 
steroid receptor expression levels of T47D breast cancer cells 
 




In summary, it is possible that E2, as well as all the progestogens may influence breast cancer 
development and progression by downregulating steroid receptors such as the ER-subtypes, PR-
isoforms and the AR, but not the GR in T47D breast cancer cells.  
4.3. Although neither IL-6 nor TNFα influenced steroid receptor expression levels in 
the T47D breast cancer cells, TNFα upregulated the expression of the GR. 
While it is known that steroid receptors as well as pro-inflammatory mediators, play important roles 
in breast cancer biology, the precise mechanisms are not known (Lazennec et al., 2001; Cops et al., 
2008; Tan et al., 2009). To the best of our knowledge, this is the first study to evaluate whether IL-6 
and TNFα influence steroid receptor expression in a breast cancer cell line, and whether they 
influence hormone-induced effects on steroid receptor expression. Neither IL-6 nor TNFα influenced 
the expression levels of either PR-isoforms, or the ER-subtypes or the AR in T47D breast cancer 
cells, while TNFα upregulated the expression of the GR (Figure 3.1-Figure3.3; Table 4.1). Moreover, 
neither of these cytokines modulated the effects of the hormones on any of these steroid receptors 
(Figure 3.1-Figure3.3). The increase in GR protein expression in response to TNFα correlates with a 
previous study that showed the same effect in the human cervical adenocarcinoma (HeLaS3) and 
human lymphoid (CEMC7) cells (Webster et al., 2001). These authors showed that TNFα increases 
GR expression in the HeLaS3 and the CEMC7 cells via a mechanism involving the binding of NF-
κB to its DNA binding site upstream to the human GR promoter (Webster et al., 2001). Thus, it is 
likely that TNFα increases GR expression in T47D breast cancer cells in a similar manner. As GR 
expression in ER+ breast cancer has been associated with a good prognosis (Pan et al., 2011), an 
increase in GR expression by TNFα may suggest a favourable outcome in ER+ breast cancer. 
4.4. E2 and the progestogens may lead to the survival of breast cancer cells. 
Cancer cells can sustain proliferative signalling while evading cell death signals, ultimately 
contributing to the successful survival of the disease (Hanahan et al., 2000; Evan and Vousden, 2001; 
Hanahan and Weinberg, 2011). The literature regarding the effects of the progestins on breast cancer 
cell survival are contradictory. In this study, a direct comparison of the effects of E2, P4 and selected 
progestins showed that these hormones differentially regulated proliferation of two ER+ breast cancer 
cell lines (Figure 3.4 and summarised in Table 4.2). The increase in proliferation of the T47D and 
MCF-7 BUS cells in response to P4 (Figure3.4A and B) is consistent with two other studies (Liang et 
al., 2006; Tian et al., 2018), whilst others have shown that P4 inhibits proliferation of T47D and MCF-
7 cells (Groshong et al., 1997; Formby et al., 1998; Ruan et al., 2012). Interestingly, the results of 
the current study showed that DRSP and NoMAC had no effect on the proliferation of both cell lines, 




while the proliferation by all ligands except LNG, were higher in the estrogen-sensitive MCF-7 BUS 
cell line (Figure 3.4C). Furthermore, LNG was the only progestin eliciting cell line-specific effects, 
indicated by the fact that it increased proliferation of the T47D cells, while having no effect on 
proliferation of the MCF-7 BUS cells (Figure 3.4C). Considering that at least two studies have 
previously shown that LNG increases the proliferation of MCF-7 cells (Van den Burg et al., 1992; 
Schoonen et al., 1995), a similar response was expected in the MCF-7 BUS cells, as this highly 
estrogen-responsive cell line was originally cloned from the MCF-7 breast cancer cell line (Villalobos 
et al., 1995). Thus, the lack of proliferation in response to LNG in the MCF-7 BUS cells are surprising 
and hard to interpret, especially since MPA, NET-A, LNG and GES have similar activities via the 
PR, AR and ERα (Africander et al., 2011, 2014; Louw-du Toit et al., 2017). Importantly, results 
showing that the fourth-generation progestins, DRSP and NoMAC, have no effect on proliferation of 
either T47D or MCF-7 BUS breast cancer cell lines (Figure3.4), suggest that these hormones may be 
a safer HT option than the earlier-generation progestins in terms of breast cancer risk. However, it 
should be noted that the French E3N-EPIC cohort study investigating the risk of breast cancer 
associated with HT use by postmenopausal women, has shown that NoMAC, combined with 
estrogen, is in fact associated with increased breast cancer risk (Fournier et al., 2008). It is important 
to remember that the development and progression of breast cancer is dependent on a number of 
regulatory processes. Thus, the observed effects of the progestins on proliferation should be 
considered in the light of the fact that there may be a balance between these processes. 
Results from the Caspase-Glo 3/7 apoptosis assay used in this study, showed that none of the 
hormones induced apoptosis of either the T47D or the MCF-7 BUS breast cancer cell lines (Figure 
3.9A and B, and summarised in Table 4.2). The results showing that Tamoxifen, a known inducer of 
apoptosis, induced apoptosis in the T47D cells, while TNFα induced apoptosis in the MCF-7 BUS 
cells (Addendum B, Figure B5), indicated that the apoptosis assay was functional in both these cell 
lines. Our results showing no effect with that E2 and the progestogens on apoptosis are contradictory 
to previous studies that have shown that E2 (Gompel et al., 2000; Helguero et al., 2005; Lewis-Wambi 
and Jordan, 2009), MPA as well as NET-A can inhibit apoptosis in the T47D and MCF-7 cells (Ory 
et al. 2001; Sweeney et al. 2014). Similarly, studies have shown that P4 can either induce (Formby 
and Wiley, 1998, 1999) or inhibit (Moore et al., 2006) apoptosis of T47D breast cancer cells. The 
difference between our results and these studies could possibly be due to the use of different assays. 
For example, Formby and Wiley, measured apoptosis by assays such as fluorescence activated cell 
sorting (FACS), semi-quantitative reverse transcriptase (RT)-PCR and immunoblotting for caspase 3 
expression (Formby and Wiley, 1998). Differences in apoptotic effects when using different assays 
are also reflected in our own results. We showed that both E2 and MPA increased the mRNA 




expression of the pro-apoptotic Bax gene in the T47D cell line (Figure 3.8A), while having no effect 
on the Bcl-2 gene (Figure 3.8B). Neither E2 nor MPA had an effect on the mRNA expression of either 
Bax or Bcl-2 in the MCF-7 BUS cell line (Figure 3.8C and D), suggesting that effects on apoptosis 
are also cell-specific. Taken together, the overall increase observed in proliferation of both the T47D 
and MCF-7 BUS cells in response E2, P4, MPA, NET-A, and GES, as well as LNG in the T47D cells, 
and the likely lack of induction of apoptosis, suggests that these hormones may lead to the survival 
of these breast cancer cells. 
Table 4.2 Summary of the effects of E2, the progestogens and the inflammatory mediators on 
the proliferation and apoptosis of T47D and MCF-7 BUS breast cancer cells. 
 
4.5. Unlike IL-6, TNFα significantly decreased the cell viability and induced apoptosis of 
the MCF-7 BUS cell line, while having no effect on the growth of the T47D breast 
cancer cell line. 
Evidence in the literature regarding the effects of IL-6 and TNFα on the proliferation and apoptosis 
of breast cancer cells are contradictory. Some studies have reported that both IL-6 and TNFα increase 
breast cancer cell proliferation, whereas others state that these cytokines inhibit cell proliferation. 
(Rubio et al., 2006; Sasser et al., 2007; Studebaker et al., 2008). Results from this study showed that 
IL-6 had no effect on the proliferation of either the T47D or MCF-7 BUS cells (Figure 3.5A and B; 
Table 4.2), neither did it modulate the hormone-induced effects on proliferation of either cell line 
(Figure 3.5A and B). At least one other study has also shown that IL-6 has no effect on the 
proliferation of MCF-7 breast cancer cells (Jiang et al., 2011), while two other studies have shown 
that IL-6 increases proliferation of this cell line (Sasser et al., 2007; Studebaker et al., 2008). In terms 




of TNFα, it has previously been shown that it promotes apoptosis (Simstein et al., 2003) in MCF-7 
cells, while stimulating proliferation of T47D breast cancer cells (Nojek et al., 2006). While we show 
that TNFα has no effect on the proliferation of T47D breast cancer cells, we do in fact observe a 
significant decrease in the viability of MCF-7 BUS cells (Figure 3.5C and D, Table 4.2). The fact that 
neither IL-6 nor TNFα increased proliferation of the T47D cells correlates with our results showing 
that neither of these cytokines had an effect on the mRNA expression of the Ki-67 proliferation 
marker in T47D cells, while its expression was significantly decreased in the MCF-7 BUS cells 
(Figure 3.6). In contrast, two other studies have shown that TNFα is associated with elevated levels 
of Ki-67 in tumour cells as well as in breast tumour tissues from mice (Baisch, 2002; Cai et al., 2017). 
Although MCF-7 BUS cell proliferation was decreased in the presence of both TNFα and the 
hormones, these effects were likely due to TNFα decreasing the cell viability, and not because TNFα 
modulated the hormone-induced effects on cell proliferation (Figure 3.5D). 
Results from the apoptosis assay confirmed that TNFα induced apoptosis in the MCF-7 BUS cells 
(Simstein et al., 2003), but not in the T47D cells (Figure 3.7, Table 4.2). Surprisingly, IL-6 and TNFα 
both increased the mRNA expression of Bax and Bcl-2 in the T47D cells, while having no effect on 
these genes in the MCF-7 BUS cells (Figure 3.8, Table 4.2). The increase in both pro-and anti-
apoptotic genes in response to the cytokines (Figure 3.8A and B), may explain the lack of an overall 
effect on apoptosis in the T47D breast cancer cells using the Caspase-Glo 3/7 assay (Figure 3.7A), as 
the prediction of cell survival is determined by the function of both these proteins. Furthermore, the 
combination of IL-6 or TNFα with E2 or the progestogens, also had no effect on the apoptosis of 
T47D breast cancer cells (Figure 3.9C). The increased apoptosis in MCF-7 BUS cells in the presence 
of TNFα and the hormones, was likely due to TNFα inducing apoptosis and not as a result of the 
combination of TNFα and the hormones (Figure 3.9D). Taken together, and in agreement with 
previous studies (Simstein et al., 2003; Martínez-reza et al., 2017), our results show that TNFα 
induced apoptosis in the MCF-7 BUS cells, while having no effect on the T47D cells. Moreover, 
these cytokines did not modulate the hormone-mediated effects on either proliferation or apoptosis 
4.6. Both IL-6 and TNFα, as well as E2 and the progestins, increased the migration of 
the T47D breast cancer cell line, while the effects of the hormones could not be 
modulated by these inflammatory mediators. 
Cancer cells can also migrate and invade, and 90% of cancer related deaths are due to these processes 
(Hanahan et al., 2000; Wolczyk et al., 2016). To date, studies investigating the effects of E2 and the 
progestogens on breast cancer cell migration and invasion are limited. Some, however, have shown 
that E2 causes an increase in migration of T47D (Zheng et al., 2011) and MCF-7 breast cancer cells 




(Shang et al., 2015). Similarly, P4, MPA, and DRSP have been shown to differentially increase the 
migration of T47D breast cancer cells, with MPA causing the most migration (Fu et al., 2008). It is 
well recognised that IL-6 and TNFα increase the migration of MCF-7, T47D and MDA-MB-231 
breast cancer cells (Badache and Hynes, 2001; Wolczyk et al., 2016; Gallo et al., 2018). In this study, 
effects on migration were evaluated only in the T47D breast cancer cell line, as we had previously 
shown that TNFα decreased the cell viability of MCF-7 BUS cells (Figure 3.5D), by the induction of 
apoptosis (Figure 3.7B). We showed that E2 and all the progestins increased the migration of T47D 
breast cancer cells to a similar extent (Figure 3.12, and summarised in Table 4.3). Even though it 
appeared that P4 increased migration, this increase was not statistically different compared to the 
vehicle control. Consistent with the literature, we show that both IL-6 and TNFα increased the 
migration of the T47D breast cancer cell line (Figure 3.10 and Figure 3.11, Table 4.3) (Badache and 
Hynes, 2001; Wolczyk et al., 2016). Surprisingly, neither IL-6 (Figure 3.13B) nor TNFα (Figure 
3.14B) influenced the effects of E2 and the progestins on the migration of T47D breast cancer cells. 
The fact that IL-6 and TNFα increased the migration of T47D breast cancer cells, while having no 
effect on the proliferation of these cells, may be ascribed to the fact that these processes can occur 
independently of each other. For example, it has previously been shown that IL-6 inhibits the growth 
of T47D cells by activating the Janus kinase/signal transducers and activators of transcription 
(Jak/STAT) signalling pathway, while it simultaneously activates the mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways to enhance migration (Badache 
and Hynes, 2001). Taken together, although E2, all the progestins and both inflammatory mediators 
individually increased the migration of T47D breast cancer cells, the effects were not exacerbated 
when both hormone and inflammatory mediators were present. These results may suggest that women 
using these hormones in HT, as well as women with obesity-related inflammation, may be at risk for 
developing metastatic breast cancer. 
4.7. Neither the inflammatory mediators, nor the hormones altered MMP-2 
expression in the T47D breast cancer cell line. 
Studies have shown that E2 increases the invasion of MCF-7 (Albini et al., 1986; Thompson et al., 
1988; Jiang et al., 2013; Shang et al., 2015) and T47D breast cancer cells (van den Brûle et al., 1992). 
P4, MPA, and DRSP have also been shown to enhance invasion in these cells (Fu et al., 2008, 2010; 
Diaz et al., 2012). However, studies investigating the effects of the other progestins such as NET-A, 
LNG, GES and NoMAC on the invasion of breast cancer cells are lacking. Interestingly, IL-6 and 
TNFα have also been shown to increase invasion of MCF-7 and MDA-MB-231 breast cancer cells 
(Wolczyk et al., 2016; Gallo et al., 2018). A few studies have suggested that these cytokines may 




increase the invasiveness of cancer cells via a mechanism involving increased MMP-2 and MMP-9 
secretion (Hagemann et al., 2005; Mohamed et al., 2010; Ibrahim et al., 2016). These specific 
enzymes are gelatinases that can degrade extracellular matrix components and adhesion molecules 
such as E-cadherin (Murphy and Crabbe, 1995; Toth and Fridman, 2001; Ibrahim et al., 2016). The 
presence of these MMP’s within biological samples are often detected using the semi-quantitative 
gelatin zymography assay (Heusseneugene, 1980; Toth and Fridman, 2001). The gelatinases secreted 
from the breast cancer cells are able to exert their gelatinolytic activity in an SDS-PAGE gel 
containing gelatin, and detected as bands of clearance (Toth and Fridman, 2001; Hu and Beeton, 
2010). Results from this study showed that neither E2 or the progestogens (Figure 3.15D), IL-6 or 
TNFα (Figure 3.15C), or the combination thereof (Figure 3.15E), influenced MMP-2 levels secreted 
by T47D breast cancer cells. Wolczyk and co-workers have previously shown that TNFα has no 
significant effect on MMP-2 secretion in the MDA-MB-231 and MCF-7 breast cancer cell lines 
(Wolczyk et al., 2016). Although we could not quantify effects on MMP-9 in the T47D cells, these 
authors have also shown that TNFα dose-dependently increased the secretion of MMP-9 in MDA-
MB-231 and MCF-7 cells (Wolczyk et al., 2016).  
4.8. Preliminary results show that IL-6, MPA and DRSP appear to increase the 
invasion of the MDA-MB-231 breast cancer cell line, and that hormone-induced 
effects are decreased by TNFα. 
Effects on invasion of MDA-MB-231 breast cancer cells was next investigated using the Boyden-
chamber transwell assay, as attempts of this assay in both the T47D and MCF-7 BUS cells were 
unsuccessful. The MDA-MB-231 cell line was used as it is highly invasive compared to the T47D 
and MCF-7 cells (Gordon et al., 2003; Sarnataro et al., 2006; Sun et al., 2016). Results showed that 
both the older first-generation progestin, MPA, and the newer fourth-generation progestin, DRSP, 
appeared to increase the migration of the MDA-MB-231 cells to the same extent (Figure 3.16C and 
summarised in Table 4.3). These results are in agreement with at least one study reporting that both 
MPA and DRSP increase invasion of T47D breast cancer cells (Fu et al., 2008). In addition, our result 
showing that IL-6 appears to increase invasion of MDA-MB-231 cells (Figure 3.16C; Table 4.3), is 
consistent with a previous study (Gallo et al., 2018). In contrast, we show that TNFα appears to 
decrease the invasion of MDA-MB-231 cells (Figure 3.16; Table 4.3), while others have indicated 
that it increases the invasion of MDA-MB-231 cells (Sangmin et al., 2008; Wolczyk et al., 2016; 
Martínez-reza et al., 2017). Moreover, TNFα appears to decrease the progestin-induced invasion of 
the MDA-MB-231 breast cancer cells (Figure 3.16C). Interestingly, IL-6 also appeared to decrease 
the DRSP-induced increase in the invasion of the MDA-MB-231 cell line, while IL-6 had no effect 




on MPA-induced invasion (Figure 3.16C). Taken together, these results suggest that TNFα may 
decrease the invasion of MDA-MB-231 breast cancer cells, while MPA and DRSP as well as IL-6 
may increase invasion. Moreover, co-treatment with MPA or DRSP, in the presence of either of these 
proinflammatory cytokines, may decrease breast cancer cell invasion. However, as these results were 
from a single experiment, no definitive conclusions can be drawn on the effects of MPA, DRSP, IL-
6 and TNFα on the invasion of the MDA-MB-231 breast cancer cell line.  
Table 4.3 Summary of the effects of E2, selected progestogens and the inflammatory mediators 
on the migration and invasion of breast cancer cell lines. 
 
4.9. Conclusions and future work 
Multiple progestins with different structures and biological activities are used in contraception and 
menopausal HT (Africander et al., 2011; Stanczyk et al., 2013). Alarmingly, a number of these 
progestins have been associated with increased risk of invasive breast cancer (Rossouw et al., 2002; 
Million Women Study Collaborators, 2003; Fournier et al., 2008). It is noteworthy that not all 
progestins have been evaluated in terms of breast cancer risk, and that the exact mechanism whereby 
some progestins contribute to increased breast cancer risk is not clear. Although these hormones were 
designed to mimic the activity of P4 via the PR, it can also act via other steroid receptors such as the 
GR, AR and ER (Koubovec et al., 2005; Guerra et al., 2013; Stanczyk et al., 2013; Africander et al., 
2014; Louw-du Toit et al., 2017). Considering the important roles that these steroid receptors play in 
breast cancer (Ali and Coombes, 2000; Hopp et al., 2004; Conzen, 2008; Robinson et al., 2011; Rizza 
et al., 2014; Karamouzis et al., 2015; Thomas and Gustafsson, 2015), we evaluated effects of selected 
progestins on steroid receptor expression. We provide evidence that all progestins evaluated 
downregulated the expression of the PR-isoforms, ER-subtypes and the AR, while having no effect 
on the expression of the GR. In ER+ breast cancer, the decreased expression of the PR and AR may 
be associated with a poor prognosis, as it is known that activated PR and AR decrease ERα-mediated 
signalling (Lanzino et al., 2005; Peters et al., 2009; Rizza et al., 2014; Mohammed et al., 2015). In 
contrast, the decrease in both ER subtypes, suggests an overall decrease in ER signalling, which may 
suggest a favourable outcome in terms of breast cancer. However, steroid receptor signalling in breast 




cancer is quite complex, and further investigation would be needed to evaluate the precise 
physiological impact of these results. While we showed that some progestogens increased cell 
survival, all progestins, unlike P4, increased migration of T47D breast cancer cells, suggesting that 
progestins may be associated with an increased risk for developing metastatic breast cancer. Even 
though we showed that DRSP and NoMAC have no effect on the proliferation of T47D and MCF-7 
BUS breast cancer cells, both these hormones enhanced the migration of T47D breast cancer cells. 
The pro-inflammatory cytokines, IL-6 and TNFα, have also previously been linked to breast cancer 
risk (MacCiò et al., 2009; MacCiò and Madeddu, 2011; Iyengar et al., 2013). Our hypothesis that 
breast cancer would be increased in the presence of both progestin and either IL-6 or TNFα was 
disproved. To the best of our knowledge, we are the first to show that neither IL-6 nor TNFα 
modulated the effects of the progestins on steroid receptor expression levels in T47D breast cancer 
cells. We also provide evidence that these cytokines do not modulate the effects of the progestins on 
proliferation, apoptosis and migration of breast cancer cells. Our results do however confirm that both 
IL-6 and TNFα increased the migration of T47D breast cancer cells, which may contribute to an 
aggressive form of breast cancer. In summary, none of the results obtained in this study indicate that 
the effects of the progestins were exacerbated by the addition of the inflammatory mediators.  
The present study has a few shortcomings that should be addressed in future studies. For example, 
this study investigated a single concentration of the progestins and the proinflammatory cytokines. 
The serum concentration levels of injectable contraceptives ranges up to ± 60 nM a few days post 
injection (Focan et al., 2001; Africander et al., 2011; Blode et al., 2012; Gerrits et al., 2013; Louw-
du Toit, Perkins, et al., 2016; Louw-du Toit et al., 2017), while  serum concentrations of progestins 
used in HT are not easily found in the literature. However, it has been reported that a typical HT 
regimen of NET can result in peak plasma concentrations ranging between 3.64-17.7 nM, while oral 
administration of 0.25 mg LNG displayed a peak level of ± 15 nM within 1-3 h of administration 
(reviewed in Africander et al. 2011). The specific concentrations of IL-6 and TNFα used in this study, 
were previously used in studies investigating the effects of these cytokines on breast cancer cell 
proliferation (Chiu et al., 1996; Rubio et al., 2006; Sasser et al., 2007). However, it would be ideal 
to mimic serum concentrations of these cytokines found in obese women. While we used 5 000 pg/ml 
IL-6 and 20 000 pg/ml TNFα, serum levels of approximately 76.38 ± 45 pg/ml for IL-6 and 42.02 ± 
11.91 pg/ml for TNFα have previously been reported in obese women (Winkler et al., 2003; Park et 
al., 2005; Feitosa et al., 2013). Therefore, performing dose response analysis may provide better 
insight into the effects of physiological concentrations of progestins and cytokines on breast cancer 
biology. This is important as varying concentrations will affect receptor occupancy and lead to 
different physiological effects (Africander et al. 2011).  




Apoptosis was measured by evaluating the mRNA expression of pro- and anti-apoptotic genes, as 
well as the use of a commercial kit to evaluate the activity of caspase-3 and caspase-7. The 
investigation on the effects on the markers of apoptosis, Bcl-2 and Bax, should be extended to include 
all progestins in the absence and presence of the inflammatory mediators. A cell undergoing apoptosis 
displays many morphological and biochemical characteristics, which can differ depending on the 
inducer of apoptosis, the cell type and when the process of apoptosis is observed. The majority of 
apoptotic hallmarks can be observed by flow cytometry. Thus, future studies can assess the effects of 
the progestins and/or the inflammatory mediators using FACS, which will allow the sorting of live 
and intact cells, cells in early and late apoptosis, as well as necrotic cells (Herzenberg and Sweet, 
1976; Schellenberger et al., 2004). A major limitation of the study is that only a single experiment 
was performed to evaluate the effects of MPA, DRSP, IL-6 and TNFα on invasion of the MDA-MB-
231 breast cancer cell line. This assay should thus be repeated for all the progestins in the absence 
and presence of IL-6 and TNFα. Furthermore, this assay was only performed in the ER- MDA-MB-
231 breast cancer cell line and not in the ER+ T47D or MCF-7 cell lines. As it is known that conditions 
such as matrigel concentration and cell density can influence the invasive capability of cell lines (Hall 
and Brooks, 2014), future studies should include the optimisation of these conditions for the ER+ 
breast cancer cell lines.  
To improve our understanding of the effects of progestins and the inflammatory mediators in breast 
cancer, this study can be extended to a model for ER- breast cancer. For example, effects on the 
different hallmarks of cancer can be repeated in the MDA-MB-231 cell line. As mentioned, this study 
already investigated the effects of two of the hormones and both inflammatory mediators on invasion 
of this cell line, with preliminary results suggesting that both MPA and DRSP as well as IL-6 increase 
invasion, while TNFα decreases invasion. Moreover, considering that progestins are administered in 
combination with estrogen in menopausal HT, and some contraceptives, future studies should 
investigate the progestin responses on the different hallmarks of breast cancer in the presence of E2.  
Finally, it has been suggested that obesity is associated with an increased production of pro-
inflammatory cytokines such as IL-6 and TNFα which may contribute to the development and 
progression of breast cancer (Cole, 2009; MacCiò and Madeddu, 2011). Therefore, the focus of this 
study included the investigation of the effects of these two cytokines, also called adipokines when 
secreted by adipose cells, on breast cancer biology. However, it is also known that numerous other 
adipokines such as leptin and adiponectin, as well as IL-1β, also play important roles in breast cancer 
development and progression (MacCiò and Madeddu, 2011; Iyengar et al., 2013). Elevated levels of 
leptin and IL-1β is suggested to induce proliferation of breast cancer cells and are associated with 
increased breast cancer risk (MacCiò and Madeddu, 2011; Iyengar et al., 2013; Zahid et al., 2018). 




Thus, the role of these and other adipokines, combined with progestins, should also be investigated. 
Finally, to directly evaluate the effects of progestins, adiposity and its associated inflammation on 
breast cancer, adipose cells treated with progestins can be co-cultured with breast cancer cells.  
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ADDENDUM A  
BUFFERS AND SOLUTIONS 
  




Cell culture and Mammalian tissue culture 
Charcoal stripping buffer 
1 M sucrose 
1.5 mM MgCl2 Hexahydrate 
10 mM Hepes 
0.25% w/v Norit-A charcoal 
0.0025% w/v Dextran 
Add all together and adjust final volume to 1 L with autoclaved MilliQ H2O. 
 
Cell viability assay 
5 mg/mL MTT 
5 mg MTT 
1 mL sterile PBS  
Dissolve and filter sterilise. 
 
Electrophoresis and western blotting solutions 
2X Laemmli SDS sample buffer 
0.04 M Tris-HCl pH 6.8 
2% (v/v) SDS 
0.04% (w/v) bromophenol blue 
8% (v/v) glycerol 
2% (v/v) β-mercaptoethanol 









1X SDS PAGE running buffer  
25 mM Tris-HCl 
192 mM glycine 
0.1% (v/v) SDS 
Adjust to 1 L using RO water and store at room temperature. 
 
1X Transfer buffer 
25 mM Tris-HCl 
192 mM glycine 
10% (v/v) methanol 
Adjust to 1 L using RO water and store at 4°C. 
 
10X Tris-buffered saline (TBS) 
50 mM TRIS 
150 mM NaCl  
Dissolve in 800 mL dH2O and adjust pH to 7.5 
Adjust volume to 1 L with dH2O 
Store at 4 °C for up to three months. 
 
1X TBS-Tween (TBST) 
100 mL 10X TBS and 900 mL dH2O 











Gelatin Zymography assay 
4X Sample buffer 
0.28 M Tris-HCl (pH 6.8) 
44% glycerol 
0.31 M SDS 
0.01% (w/v) bromophenol blue 
Dissolve and store at room temperature. 
 
Coomassie Blue stain solution 
5% (v/v) methanol 
10% (v/v) acetic acid 
1% (w/v) Coomassie Blue 
Adjust to 100 mL with RO water and store at room temperature. 
 
Destain solution  
40% (v/v) methanol 
7% (v/v) acetic acid 
Adjust to 1 L with RO water and store at room temperature. 
 
Renaturing buffer 
2.5% (v/v) Triton X 
Adjust volume to 1 L with RO water and store at room temperature. 
 
  





50 mM Tris-HCl (pH 7.4) 
10 mM CaCl2 
0.02% (w/v) NaN3 















ADDENDUM B  
ADDITIONAL DATA  




B1. T47D, MCF-7 BUS and MDA-MB-231 breast cancer cells used in this study were mycoplasma negative 
 
Figure B1. Mycoplasma negative (A) T47D, (B) MCF-7 BUS and (C) MDA-MB-231 breast cancer cells. Cells were fixed with a ratio of 3:1 methanol to glacial acetic acid before 
staining with the DNA Hoechst 33258 dye (Sigma-Aldrich, SA). The Hoechst dye only stains DNA-containing nuclei. Fluorescent images were captured using the Olympus IX81 
inverted fluorescence microscope. 
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B2. RNA isolated from T47D and MCF-7 BUS breast cancer cells were intact 
 
Figure B2. Representative 1% denaturing agarose gel indicating intact RNA isolated from T47D and MCF-7 BUS 
breast cancer cells. Total RNA was isolated from T47D (lanes 1-3) and MCF-7 BUS (lanes 4-5) breast cancer cell lines 
treated with either 0.1% (v/v) EtOH (lanes 1 and 4), 5 ng/ml IL-6 (lanes 2 and 5) or 20 ng/ml TNFα (lanes 3 and 6). RNA 
was isolated using Tri-reagent as described in Chapter 2, Section 2.8. A total of 1 μg RNA was loaded onto the agarose 
gel, and the RNA was visualised with Nancy-520 nucleic acid stain.  
 




B3. A single amplicon was obtained for the Ki-67, Bax, Bcl-2 and GAPDH target 
genes 
 
Figure B3. Representative melting curves obtained for the genes evaluated in this study. Single melting curves were 
generated for (A) Ki-67, (B) Bax, (C) Bcl-2 and (D) GAPDH using the LightCycler® 96 software. The grey lines represent 
the no template negative control. 




B4. The correct qPCR products were confirmed with agarose gel electrophoresis 
 
Figure B4. Representative agarose gels indicating qPCR products of (A) Ki-67, (B) Bax, (C) Bcl-2 and (D) GAPDH. 
PCR products were subjected to agarose gel electrophoresis (2% w/v), and visualised with Nancy-520 nucleic acid stain. 
M: GeneRuler 100 bp DNA Ladder (Thermo Scientific, USA), S: sample treated with 0.1% (v/v) EtOH, NT: no template 
negative control. 
 




B5. The optimal cell density for the Caspase-Glo 3/7 apoptosis assay in both the 
T47D and MCF-7 BUS cells was 1 x 103 cells per well 
 
Figure B5. The optimal cell density for both the T47D and MCF-7 BUS cell lines was 1x103 cells per well. T47D 
and MCF-7 BUS breast cancer cells were seeded at either 1 x 103, 5 x 103 or 1 x 104 cells per well and allowed to settle. 
Cells were treated with either 0.1% (v/v) EtOH (vehicle), 25 μM Tamoxifen, 5 ng/ml IL-6 or 20 ng/ml TNFα for 24 and 
6 hours, respectively. The Caspase-Glo 3/7 luminescent assay was used to determine caspase-3 and 7 activities, as a 
measure of apoptosis. Results are expressed as fold caspase 3/7 activity relative to EtOH (vehicle) set as 1, and are 
representative of a single experiment performed in triplicate. 
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